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G protein-coupled receptors (GPCRs) are the largest family of signaling proteins in 
animals and represent the largest family of druggable targets in the human genome. 
Therefore, it is of no surprise that the molecular mechanisms of GPCR activation and 
signal transduction have attracted close attention for the past few decades. Several 
stabilizing interactions within the GPCR transmembrane (TM) domain helices regulate 
receptor activation. An example is a salt bridge between 2 highly conserved amino 
acids at the bottom of TM3 and TM6 that has been characterized for a large number of 
GPCRs. Through structural modeling and molecular dynamics (MD) simulations, we 
predicted several electrostatic interactions to be involved in metabotropic glutamate 
receptor 2 (mGlu2R) activation. To experimentally test these predictions, we employed 
a charge reversal mutagenesis approach to disrupt predicted receptor electrostatic 
intramolecular interactions as well as intermolecular interactions between the receptor 
and G proteins. Using two electrode voltage clamp in Xenopus laevis oocytes 
  xiii 
expressing mutant receptors and G-proteins, we revealed novel electrostatic 
interactions, mostly located around intracellular loops 2 and 3 of mGlu2R, that are 
critical for both receptor and G-protein activation. These studies contribute to elucidating 
the molecular determinants of mGluRs activation and conformational coupling to G-
proteins, and can likely be extended to include other classes of GPCRs.
  1 
Chapter 1 INTRODUCTION 
1.1 GPCR to G-protein Signaling 
G protein-coupled receptors (GPCRs) are the largest family of signaling proteins in 
animals, and represent the largest family of druggable targets in the human genome 
(Wacker, Stevens, and Roth 2017). Many disorders have been linked to mutations and 
polymorphisms in GPCRs. Therefore, the molecular mechanisms of GPCR activation 
and signal transduction have attracted close attention for the last half century.  
The general structure of all GPCRs is the same: an extracellular amino terminus, a 
seven-transmembrane helical domain (TMD), an intracellular carboxy terminus, and 6 
loops (3 extracellular and 3 intracellular) connecting the TMD helices. GPCRs vary in 
the length of N-terminal domain, intracellular loops, and C-terminus (Fig. 1.1).  
In simplest terms, GPCRs serve as signal transducers. They transduce extracellular 
signals, whether induced by hormones, neurotransmitters, photons, odorants, tastants, 
or other small molecules, into intracellular signaling events (Lefkowitz 2007). This 
common theme unifies the cellular function of the hundreds of GPCRs involved in 
numerous physiological processes.  
As with GPCRs, heterotrimeric guanine nucleotide-binding proteins (G-proteins) 
represent another essential family of signaling proteins that has been highly conserved 
over evolution. Each G-protein heterotrimer consists of Gα, Gβ, and Gγ subunits. Each 
subunit has distinctive isoforms including 16 Gα, 5 Gβ, and 13 Gγ isoforms in humans 
that assemble in distinct combinations, which contribute to the specificity with regards to 
both GPCRs and effector systems (Milligan and Kostenis 2006). G-proteins function to 
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transduce signals from this vast array of receptors to protein effectors such as ion 
channels and enzymes, thus regulating the levels of intracellular second messengers. 
In the absence of ligand, the affinity of the G-protein to the GPCR is low, and the Gα 
subunit of the heterotrimer, which contains the nucleotide binding site, is bound to 
guanine diphosphate (GDP) forming the inactive heterotrimer (Fig. 1.2). Ligand-induced 
receptor activation promotes the engagement of the GDP-bound heterotrimer and 
accelerates GDP dissociation , the rate-limiting step in G-protein activation. The 
resulting nucleotide-free receptor–G-protein complex has a very short lifetime because 
the high intracellular GTP concentration facilitates rapid GTP binding to the nucleotide-
binding site of Gα. The GTP-bound Gα undergoes conformational changes that result in 
the dissociation from Gβγ subunits. Both elements of the G-protein can regulate the 
activity of effector proteins such as adenylyl cyclases (ACs), phospholipases, and ion 
channels (Table 1.1). The cycle is terminated by hydrolysis of GTP to GDP either via 
the intrinsic GTPase activity of the Gα subunit or accelerated by GTPase-activating 
proteins, the largest family of which are the regulators of G-protein signaling (RGS) 
proteins. This leads to the reassociation of the Gα and Gβγ subunits into the inactive 
heterotrimer complex (Milligan and Kostenis 2006).  
G proteins can be generally grouped into 4 families: Gαs, Gαi, Gαq, and Gα12 (Table 
1.1). Traditionally, G protein-mediated responses have been classified into pertussis 
toxin (PTX)- sensitive and PTX-insensitive responses, because of the ability of this 
bacterial toxin to selectively inactivate G proteins of the Gi family (Fig. 1.3). This 
property is widely exploited to test for the involvement of Gi in cellular responses. At the 
molecular level, PTX ADP-ribosylates the Gαi subunit functionally uncoupling Gi 
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proteins from GPCRs, and thereby, preventing their activation (Vauquelin and Von 
Mentzer 2008).   
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1.2 GPCR Activation 
1.2.1 GPCR Activation Models 
GPCRs were first described to exist in two distinct conformations, active and inactive, 
akin to the open and closed states of an ion channel. This binary “on-off switch” idea 
was the basis for the classical ternary complex model of GPCR-driven signaling (De 
Lean, Stadel, and Lefkowitz 1980). This view considered the activation of a receptor by 
an agonist to produce a ternary complex with the G protein, thus activating the G protein 
to initiate a cellular response. However, a number of biophysical studies have shown 
that GPCRs are dynamic proteins that can sample multiple conformations (Manglik et 
al. 2015; Yao et al. 2009). Accumulating evidence has supported an alternative multi-
state model where GPCRs can adopt multiple conformational states that exist in an 
equilibrium dependent on the bound ligand and the interacting cognate G protein 
(Gurevich and Gurevich 2017; Samama et al. 1993; Ghanouni et al. 2001). This 
conformational equilibrium cannot be shifted to a single inactive or active conformation, 
which explains the reported constitutive activity of many GPCRs (Seifert and Wenzel-
Seifert 2002; Costa and Herz 1989). Depending on its intrinsic efficacy, a ligand can 
shift the equilibrium to increase the proportion of receptors in active conformational 
states in the case of agonists, or to stabilize receptors in more inactive conformations in 
the case of inverse agonists (Fig. 1.4). Moreover, different intracellular signaling 
proteins might prefer distinct receptor conformations, adding more complexity to the 
multitude of cellular effects a ligand-bound receptor can initiate. The ability of ligands to 
stabilize some unique conformational states activating certain cellular pathways and not 
others has been termed “biased signaling”, functional selectivity”, and “stimulus 
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trafficking” (Urban et al. 2007; Conn, Christopoulos, and Lindsley 2009). Biased 
signaling provides a potential opportunity to selectively target signaling pathways critical 
for therapeutic efficacy and exclude other pathways associated with adverse effects.   
1.2.2 Targetable Sites on GPCRs 
GPCRs have been classically targeted through their endogenous ligand (orthosteric)-
binding site. This approach has often failed to yield highly selective orthosteric 
compounds. This can be explained by the fact that orthosteric sites are often highly 
conserved between subtypes of a single GPCR subfamily which renders the 
development of subtype-selective orthosteric ligands challenging. 
An alternative relatively recent approach has been to target allosteric sites — sites that 
are spatially distinct from, but conformationally linked to, the orthosteric site (Fig. 1.5.A). 
Allosteric modulators can modify the action of the orthosteric ligand by modulating its 
affinity and/or efficacy (Fig. 1.5.B), either in a positive (in case of positive allosteric 
modulators, PAMs) or a negative direction (in case of negative allosteric modulators, 
NAMs) (Ellaithy et al. 2015). This phenomenon is referred to as ‘cooperativity’ (Conn, 
Christopoulos, and Lindsley 2009). PAMs enhance the response to an agonist and 
cause a leftward (and often an upward) shift in the concentration–response curve for the 
orthosteric agonist. Interestingly, a PAM can behave either as a pure PAM, eliciting no 
detectable response in the absence of the orthosteric agonist, or as an ago-PAM that 
can directly activate a receptor. NAMs noncompetitively antagonize agonists and cause 
a rightward (and often downward) shift in the agonist concentration-response curves 
(Fig. 1.5.B). Neutral allosteric ligands occupy the allosteric site without affecting the 
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agonist responses; yet, they can block the effects of both PAMs and NAMs 
(Christopoulos et al. 2014). 
PAMs have an advantage over synthetic orthosteric agonists in their ability to maintain 
the temporal and spatial fidelity of receptor signaling (Fig. 1.6) because their effects are 
dependent on the presence of the endogenous ligand. Unlike synthetic orthosteric 
agonists, PAMs will not continuously activate the receptor, thus receptor desensitization 
and/or downregulation is less likely to occur. Moreover, an allosteric drug  is more likely 
to fine-tune physiological responses with less risk of toxicity since no effect is expected 
at saturating concentrations above that determined by cooperativity (Christopoulos 
2014). This saturability phenomenon is referred to as the ‘ceiling level’ of the allosteric 
effect.  
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1.3 Structural Basis of GPCR–G protein interactions 
The idea that different GPCRs have common molecular activation mechanisms allowing 
diverse extracellular stimuli to utilize shared downstream signaling molecules was 
proposed in the late 1980s based on the structural homology of GPCRs (Strader, Sigal, 
and Dixon 1989). However, GPCRs are inherently challenging proteins for structural 
studies largely due to their conformational plasticity, and until recently, high-resolution 
structures that allow mechanistic understanding of receptor activation have been 
impossible to obtain. This has changed over the past decade thanks to advances in 
structural biology that allowed unprecedented detailed examination of the mechanisms 
underlying receptor activation (Manglik and Kruse 2017).  
1.3.1 Conformational Changes Involved in Receptor Activation 
Several conserved structural rearrangements, referred to as ‘‘molecular switches”, 
regulate receptor activation. Such conformational changes are best appreciated through 
comparing crystal structures of the same receptor in active and inactive states. 
1.3.1.1 Outward Movement of TM6  
The most prominent change seen in all GPCRs examined so far is a movement of the 
intracellular end of TM6 away from the middle axis of the TMD (Fig. 1.7) (Farrens et al. 
1996; Altenbach et al. 2008). This creates a cavity on the cytoplasmic face of the 
receptor that can accommodate the Gα C-terminus (Manglik and Kruse 2017).  
1.3.1.2 The Ionic Lock 
The “ionic lock” is a common feature of many GPCRs where Arg3.50 in the highly 
conserved D(E)RY motif at the intracellular end of TM3 serves to stabilize the receptor 
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in an inactive state through a salt bridge to Glu6.30 (Fig. 1.8). This interaction holds the 
cytoplasmic ends of TM3 and TM6 in close vicinity, thus constraining the receptor in an 
inactive state (Palczewski et al. 2000; Wang et al. 2018; Rasmussen et al. 2007; Vogel 
et al. 2008). Breakage of this lock has been postulated to be a critical step in receptor 
activation since disruption of the ionic lock through mutations increases the constitutive 
receptor activity (Shapiro et al. 2002; Ballesteros et al. 2001; Rasmussen et al. 1999; 
Scheer et al. 1997; Scheer et al. 1996; Alewijnse et al. 2000).  
1.3.1.3 The NPxxY motif 
Another important sequence motif that shows significant rearrangements upon 
activation is the NPxxY motif located near the intracellular end of TM7. The sequence 
contains a highly conserved tyrosine (Tyr7.53) which, on activation, changes its rotamer 
conformation and points towards the core of the TMD allowing the formation of a 
hydrogen bond between the NPxxY motif and the highly conserved Tyr 5.58 in TM5. 
This interaction stabilizes the receptor active conformation in a manner analogous to 
how the ionic lock interaction stabilizes the inactive conformation (Manglik and Kruse 
2017).  
Most of the previously mentioned structural rearrangements have been characterized in 
class A GPCRs, but more evidence is revealing other families of GPCRs are utilizing 
several of the same mechanisms.  The outward motion of TM6 has been shown in the 
crystal structures of activated class B GPCRs (Liang et al. 2017; Zhang et al. 2017; 
Jazayeri et al. 2017), and the ionic lock has been revealed in the inactive crystal 
structures of the class C GPCRs metabotropic glutamate receptors mGlu1R and 
mGlu5R (Doré et al. 2014; Wu et al. 2014). The remarkable degree of conservation of 
  9 
these structural rearrangements even among distantly related receptors with little 
primary sequence homology suggests a common evolutionary origin for the activation 
mechanisms in most GPCRs (Manglik and Kruse 2017). 
1.3.2 Allosteric coupling between agonist-binding and nucleotide-binding 
sites in GPCRs 
Structural studies have revealed that full agonists alone, even those with picomolar 
affinity, do not completely stabilize a fully active receptor conformation as further 
receptor activation, including a greater outward movement of TM6, is observed upon 
addition of the heterotrimeric Gs protein or the Gs-mimetic nanobody Nb80 (Rasmussen 
et al. 2011; Yao et al. 2009; Nygaard et al. 2013; Manglik et al. 2015; Sounier et al. 
2015; Isogai et al. 2016). This suggests that the allosteric coupling between agonist-
binding and nucleotide-binding sites is loose, that is, agonist binding is not necessarily 
translated into a fully active receptor conformation. Rather, agonist binding serves to 
enhance the probability of sampling intermediate active states that are conducive to 
interaction with the G protein. After achieving a G protein-interacting conformation and 
engaging GDP-bound G protein, the receptor functions to accelerate GDP dissociation 
from Gα by allosterically disrupting the nucleotide-binding site (Mahoney and Sunahara 
2016).  
1.3.3 Receptor-catalyzed nucleotide exchange  
Earlier than for GPCRs, crystal structures for G proteins have been determined in their 
active (GTPγS-bound), transition (GDP·AlF4-bound), and inactive (GDP-bound) states 
(Noel, Hamm, and Sigler 1993; Sunahara et al. 1997; Coleman et al. 1994; Mixon et al. 
1995; Lambright et al. 1996; Lambright et al. 1994; Sondek et al. 1994). These 
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structures revealed that the nucleotide is buried at the interface between the 2 domains 
of Gα subunit, the Ras-homology domain (RHD) and the α-helical domain (AHD) (Fig. 
1.9), and suggested a requirement for domain separation for nucleotide entry or exit 
from its binding pocket.  
While domain separation is required for nucleotide release, it has been revealed that 
GDP remains bound to the RHD upon separation of the two domains or even when the 
entire AHD has been deleted (Dror et al. 2015). This suggests that GDP dissociation 
needs to be triggered through other receptor-mediated conformational changes within 
the RHD that are transmitted to the nucleotide-binding site to promote nucleotide 
release (Hilger, Masureel, and Kobilka 2018).  
Numerous studies have identified several receptor contact sites on G-protein (Fig. 
1.9A) (Oldham and Hamm 2008). Those are specific parts of Gα N terminus (αN), C 
terminus (αC), α3–β5 loop, and α4–β6 loop. The reorientation places the nucleotide 
∼30 Å from the sites of nearest receptor contact, posing the question of how receptors 
cause GDP release from this distance (Oldham and Hamm 2008). 
Two potential allosteric connections have been suggested for propagation of 
conformational changes from the activated receptor to the nucleotide-binding pocket 
(Mahoney and Sunahara 2016): 
Gα C-terminus: Comparison of the interactions formed by the C-terminal α5 helix of Gα 
in GDP-bound structures (Scheerer et al. 2008; Choe et al. 2011; Standfuss et al. 2011) 
and in the β2AR-bound nucleotide-free state (Rasmussen et al. 2011) shows that upon 
receptor binding, the distal C-terminus rotates approximately 60° and translates 5 A° up 
to embed into the cavity opened by the outward rotation of receptor’s TM6, leading to 
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several rearrangements within the Gα RHD (Mahoney and Sunahara 2016). The most 
important rearrangement is that of β6-α5 loop, which directly contacts the purine base 
through the conserved TCAT motif (Fig. 1.9A), resulting in a decrease in the affinity of 
the bound nucleotide (Dror et al. 2015). 
Gα N-terminus: The N-terminal helix (αN) of Gα subunits is followed by the β1-strand, 
which in turn is followed by the β1–α1 loop — also known as the P-loop — a highly 
conserved structural feature of both small molecular weight and heterotrimeric G 
proteins that coordinates the α- and β-phosphates of GDP. Interaction of the αN with 
ICL2 of the activated receptor (Rasmussen et al. 2011) perturbs the P-loop-GDP 
interaction triggering nucleotide release from G-protein (Chung et al. 2011).  
The role of αN also helps explain the involvement of Gβγ in nucleotide exchange. In the 
heterotrimer, Gβγ helps to position the αN in a conformation that engages ICL2 of the 
receptor allowing for receptor-catalyzed nucleotide release, without actually making 
contact with the receptor (Mahoney and Sunahara 2016). 
The process of GDP dissociation may require the cooperative engagement of both N- 
and C- termini by the receptor (Mahoney and Sunahara 2016). The crystal structure of 
A2AR-mini Gαs complex that lacked the N-terminus-ICL2 interaction and remained GDP-
bound supports this idea (Carpenter et al. 2016). Which Gα terminus engages the 
receptor first remains to be determined.  
1.3.4 G protein feedback to the agonist-binding site  
It has been shown that the ligand-binding affinity of the receptor is enhanced when 
engaged by G protein or nanobodies that behave as G protein mimics (e.g. Nb80) 
(Rasmussen et al. 2011; Huang, Manglik, et al. 2015; Kruse et al. 2013). Several GPCR 
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crystal structures reveal conformational changes in the extracellular loops the result in 
the formation of a lid-like structure above the ligand binding site (Isogai et al. 2016; 
DeVree et al. 2016). This active closed conformation of the receptor hinders ligand 
dissociation, which explains the G protein-mediated effects on enhancing agonist 
binding affinity (Mahoney and Sunahara 2016). 
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1.4 Metabotropic Glutamate Receptors 
1.4.1 The Glutamatergic System 
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous 
system (CNS). It plays key roles in physiological processes including learning and 
memory, as well as pathological contexts such as excitotoxic neuronal injury which 
follows CNS trauma or ischemia. Therefore, tight control of glutamatergic 
neurotransmission is necessary to maintain optimal neuronal function and prevent 
excessive activation of the system. To help achieve that, multiple levels of regulation 
have evolved (Sanacora et al. 2008). 
In the brain, glutamate can be either synthesized de novo from glucose via the 
tricarboxylic acid cycle or recycled through the glutamate/glutamine cycle. Glutamate is 
transported into synaptic vesicles by vesicular glutamate transporters (VGLUTs) where 
it is stored at high concentrations until being released in a Ca2+-dependent manner into 
the synaptic cleft by exocytosis (Sanacora et al. 2008). 
1.4.2 Ionotropic Glutamate Receptors 
There are two major categories of glutamatergic receptors in the CNS: ionotropic and 
metabotropic (Fig. 1.10). Ionotropic glutamate receptors are ligand-gated ion channels 
that open upon binding of an agonist. There are three subgroups: 
AMPA receptors. AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) 
receptors mediate the fast rapidly desensitizing excitatory current at most synapses 
which constitutes the initial response to glutamate in the synapse. They allow the inward 
flow of Na+ and the outward flow of K+ resulting in depolarization of the neuronal 
membrane (Sanacora et al. 2008).   
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Kainate receptors. Like AMPA receptors, Kainate receptors are ion channels that allow 
Na+ influx and K+ efflux mediating fast excitatory neurotransmission, but they appear to 
have a different distribution from AMPA receptors (Sanacora et al. 2008). 
NMDA receptors. N-Methyl-D-aspartic acid (NMDA) receptors are also glutamate ion 
channels that also have glycine or D-serine as coagonists. A distingusihing feature of 
NMDA receptors is their voltage-sensitive block by Mg2+.  Mg2+ blocks conductance of 
NMDA channels under basal conditions, but the blockade is overcome by partial 
depolarization of the resting membrane potential. Once Mg2+ block is overcome, NMDA 
receptors mediate the influx of not only Na+ but of Ca2+ as well. The resulting 
intracellular Ca2+ increase activates multiple enzyme cascades that are involved in 
physiological processes such as long-term potentiation, as well as pathophysiological 
conditions such as excitotoxicity associated with CNS injury (Sanacora et al. 2008).  
1.4.3 Metabotropic Glutamate Receptors 
Metabotropic glutamate receptors (mGluRs)  belong to class C GPCRs, distinguished 
by their large extracellular bilobed ligand-binding domain (LBD) and a cysteine-rich 
domain (CRD) that links the LBD to the TMD (Fig. 1.11). Another distinguishing feature 
of class C GPCRs is constitutive homo- or heterodimerization at the cell surface 
(Kniazeff et al. 2011; Romano, Yang, and O'Malley 1996; Doumazane et al. 2011). The 
eight mGluR subtypes identified so far are classified into three groups (Fig. 1.12) based 
on sequence homology, G-protein coupling, and pharmacology (Nakanishi 1992). 
Group I mGluRs (mGlu1R and mGlu5R) are predominantly coupled to Gq/11 and activate 
the phospholipase C enzyme. Group II mGluRs (mGlu2R and mGlu3R) and group III 
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(mGlu4R, mGlu6R, mGlu7R, and mGlu8R) are coupled to Gi/o proteins that inhibit 
adenylyl cyclase activity (Ellaithy et al. 2015). 
1.4.3.1 Molecular Determinants of mGluR Dimerization 
In full-length mGluRs, dimerization has been shown to be required for glutamate-
induced activation (El Moustaine et al. 2012). Dimerization of mGluRs was long thought 
to be mainly stabilized by intersubunit disulfide bridges involving the extracellular 
domains (Romano, Yang, and O'Malley 1996; Kunishima et al. 2000; Ray and 
Hauschild 2000). Recent evidence from single-molecule subunit imaging, which relies 
on counting photobleaching steps in GFP-tagged receptors, indicates that mGluR 
dimerization is primarily mediated via hydrophobic LBD interactions, with modest 
contributions from an intersubunit disulfide bridge and the TMD. Mutations that disrupt 
disulfide bridging compromises dimerization without eliminating it, unlike mutations in 
the hydrophobic dimerization interface of the LBD that result in complete 
monomerization (Levitz et al. 2016).  
1.4.3.2 Subunit Cooperativity in mGluR Activation 
Whether agonist binding to only one versus to both subunits in a dimer is required for 
receptor activation was for long subject to debate. For example, one study suggested that 
activation does not occur until two ligands bind (Kammermeier and Yun 2005), whereas 
another suggested that glutamate binding to one subunit can activate mGluRs but that 
binding to both subunits activates more efficiently (Kniazeff et al. 2004). These studies 
faced the technical difficulty of confining ligand binding to one subunit by introducing 
mutations that lower glutamate affinity in the second subunit. However, there remained a 
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concern that these mutations might have altered activation in unforeseen ways. A recent 
paper circumvented this challenge through selective liganding with photoswitchable 
tethered agonists covalently linked to one or both subunits of mGlu2R homodimers, and 
revealed that receptor activation is highly cooperative (Levitz et al. 2016). Although 
agonist binding to one subunit does activate the receptor, binding to both subunits yields 
5x more activation, indicating high cooperativity (Fig. 1.13).  
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1.5. Metabotropic Glutamate Receptor 2 as a Drug Target  
1.5.1 mGlu2R localization 
mGlu2R is widely expressed in the brain, with generally similar distribution patterns in 
human and rodent brains. Areas where mGlu2R is particularly expressed include the 
prefrontal cortex, hippocampus, striatum, thalamus, and amygdala (Ghose et al. 2009; 
Marek 2010). In addition, mGlu2Rs are primarily located presynaptically outside of the 
active zone on pre-terminal regions of axons where they can be activated by excessive 
synaptic glutamate, hence allowing them to function as an autoreceptors inhibiting 
further glutamate release and modulating synaptic transmission (Schoepp 2001).  
1.5.2 Potential applications of mGlu2R agonists/PAMs 
Due to its wide expression in the brain, heteromerization with other GPCRs (see below), 
and modulatory effect on various neurocircuits, mGlu2R has attracted considerable 
attention as a potential therapeutic target, with schizophrenia being the most explored 
clinical application to date. Other potential applications include epilepsy (Metcalf et al. 
2017), cerebral ischemia (Motolese et al. 2015; Mastroiacovo et al. 2017), 
neurodegeneration (Richards et al. 2010; Kim et al. 2010), depression (Matrisciano et 
al. 2008; Fell et al. 2011; Witkin et al. 2016), anxiety (Tizzano, Griffey, and Schoepp 
2002), cognition (Griebel et al. 2016), substance use disorders (Johnson and Lovinger 
2015; Yang et al. 2017), smoking cessation (Kenny, Gasparini, and Markou 2003), and 
chronic pain (Jones et al. 2005; Carlton, Du, and Zhou 2009). 
1.5.2.1 mGlu2R and Schizophrenia 
Schizophrenia is a chronic debilitating syndrome that affects approximately 1% of the 
general population. Symptoms are often variable but generally can be categorized into 
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positive (e.g., hallucinations, delusions, and disorganized speech and behavior), 
negative (e.g., social withdrawal, lack of motivation, flat affect), and cognitive (e.g., 
impairments in learning, memory, attention, and executive functions). These symptoms 
are typically associated with social and/or occupational dysfunction (Ellaithy et al. 2015). 
Two classes of antipsychotic drugs are currently available for the treatment of 
schizophrenia. The first generation, or typical, antipsychotics such as haloperidol and 
chloropromazine are high-affinity dopamine D2 antagonists. Because of their 
widespread blockade of dopamine, they are associated with adverse effects such as 
hyperprolactinemia and extrapyramidal symptoms. The second generation, or atypical, 
antipsychotics such as clozapine and olanzapine have less affinity for D2 receptors and 
higher affinity for the serotonin 2A receptor (5-HT2A). Although not associated with 
extrapyramidal symptoms, they are associated with weight gain and metabolic 
abnormalities such as dyslipidemia and impaired glucose tolerance (Ellaithy et al. 
2015).  
The past two decades have witnessed a rise in the ‘NMDA receptor hypofunction’ 
hypothesis for pathogenesis of schizophrenia, whereby defective NMDA receptors on 
cortical γ-amino- butyric acid (GABA) interneurons render these interneurons less 
effective in inhibiting glutamate neurons that project to the ventral tegmental area (VTA). 
This disinhibition results in excessive glutamatergic stimulation of the dopamine 
mesolimbic pathway, a key pathway, the hyperfunctioning of which has long been 
viewed to underlie schizophrenia (Schwartz, Sachdeva, and Stahl 2012). Hence, a 
variety of presynaptic, postsynaptic, and regulatory proteins involved in glutamatergic 
signaling have been proposed as potential therapeutic targets. One such target was 
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mGlu2R which is expressed in several areas implicated in the pathophysiology of 
schizophrenia such as the prefrontal cortex, hippocampus, striatum, thalamus, and 
amygdala (Ghose et al. 2009; Marek 2010). Several studies have reported 
dysregulation in mGlu2R expression levels in the brains of schizophrenic individuals 
(Bullock et al. 2008; Kordi-Tamandani, Dahmardeh, and Torkamanzehi 2013; González-
Maeso et al. 2008; Ghose et al. 2008; Gupta et al. 2005).  
mGlu2/3R agonists were shown to reverse the pro-psychotic-like effects of 
phencyclidine and psychedelic 5-HT2A receptor agonists in rodents (Moghaddam and 
Adams 1998; Cartmell, Monn, and Schoepp 1999; Moreno et al. 2012). Due to the lack 
of subtype-selective orthosteric ligands, knockout (KO) mice and Glu2R-selective PAMs 
were employed to determine whether the antipsychotic-like effects of mGlu2/3R 
agonists are mediated via mGlu2R, mGlu3R, or both. Both approaches revealed that 
these effects are predominantly mGlu2R-mediated. For example, the inhibitory effects 
of mGlu2/3R agonists on PCP- and amphetamine-evoked hyperlocomotor activity are 
absent in mGlu2R-KO but not in mGlu3R-KO mice.  
Not only does mGlu2R seem to be the target for group II mGluR antipsychotics, but it 
has also been found to crosstalk with the 5-HT2A receptor, a key target for 2nd 
generation antipsychotics. For example, the pharmacological and behavioral effects 
induced by hallucinogenic 5-HT2A agonists are abolished in mGlu2R-KO mice (Moreno 
et al. 2011). On the other hand, the locomotor activity induced by the mGlu2/3R 
antagonist LY341495 is attenuated in 5- HT2A-KO mice (González-Maeso et al. 2008). 
Similarly, the antipsychotic-like behavioral effects of LY379268 are absent in 5-HT2A-
KO mice, whereas the 5-HT2A-dependent behavioral effects of clozapine are absent in 
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mGlu2R-KO mice (Fribourg et al. 2011). Chronic treatment with the hallucinogenic 5-
HT2A agonist 2,5-dimethoxy-4-bromoamphetamine (DOB) in mice attenuates the 
behavioral effects of the mGlu2/3R agonist LY379268 (Benneyworth, Smith, and 
Sanders-Bush 2008), whereas chronic treatment by LY341495 decreases 5-HT2A 
binding and the hallucinogenic effects of lysergic acid diethylamide (LSD) (Moreno et al. 
2013).  
In heterologous expression systems, co-expression of mGlu2R with 5-HT2A potentiates 
glutamate-induced mGlu2R-coupled Gi signaling and attenuates serotonin-induced 5-
HT2A-coupled Gq signaling. Moreover, drugs that stabilize the active or inactive 
conformation in one receptor induce the opposite conformation of the partner receptor 
(Fribourg et al. 2011; Baki et al. 2016). 
Neuroanatomical approaches such as fluorescent in situ hybridization (FISH) and 
immunohistochemistry revealed an overlapping cortical distribution of mGlu2R and 5-
HT2A (González-Maeso et al. 2008; Fribourg et al. 2011). Using electron microscopy, 
both receptors were observed in close sub-cellular proximity (Moreno et al. 2012). In 
addition, 5-HT2A and mGlu2 receptors can be co-immunoprecipitated from plasma 
membrane preparations of mouse (Fribourg et al. 2011) and human (González-Maeso 
et al. 2008) frontal cortex. Taken together, these data suggest that 5-HT2A and mGlu2 
participate in a GPCR heteromeric complex with unique signaling properties. 
Clinical trials with pomaglumetad methionil (LY2140023 monohydrate; a prodrug of the 
mGlu2/3R agonist LY404039) revealed significant efficacy against positive and negative 
symptoms of schizophrenia compared to placebo. Although the efficacy was not as 
significant as for olanzapine, pomaglumetad was safe and well-tolerated and, 
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importantly, was neither associated with extrapyramidal symptoms nor with metabolic 
abnormalities, which are often problematic with the currently available antipsychotics 
(Patil et al. 2007). Subsequent phases of clinical trials showed either inconclusive 
results (Kinon et al. 2011) or results that did not separate from placebo (Hopkins 2013).  
Interestingly, recent preclinical evidence revealed that the therapeutic effects of 
pomaglumetad depend on previous exposure to antipsychotic drugs. In mouse models, 
atypical antipsychotics, such as clozapine and risperidone, but not typical ones, such as 
haloperidol, induce repressive histone modifications at the promoter region of the 
mGlu2 (Grm2) gene in the frontal cortex (Kurita et al. 2012) (Fig. 1.14). The 
translational significance of these preclinical findings has been validated recently in a 
post-hoc analysis; schizophrenia patients previously treated with atypical antipsychotics 
did not show a significant therapeutic response to pomaglumetad, whereas those who 
were treated with haloperiodol did (Kinon et al. 2015).  
Two mGlu2R PAMs are also in clinical trials. ADX71149 from Addex and Janssen, 
showed the first successful clinical proof-of-concept and demonstrated safety and 
tolerability. Patients with residual negative symptoms were identified as the 
subpopulation most likely to benefit from ADX71149 (Therapeutics 2012). The second 
compound, AZD8529 from Astrazeneca, failed to separate from placebo in a Phase IIa 
study, unlike the active control risperidone (Litman et al. 2016). However, it is worth 
mentioning that these studies did not stratify patients according to their previous 
antipsychotic treatment history.  
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1.6 Hypothesis 
Despite their physiological and pharmaceutical importance, much remains to be 
discovered about the molecular determinants of GPCR activation and coupling to G-
protein. We hypothesize that several electrostatic interactions play key roles in mGlu2R 
activation and signaling. A large number of potential mGlu2R intramolecular as well as 
mGlu2R—Gα intermolecular electrostatic interactions were suggested by structural 
modeling and molecular dynamics (MD) simulations. We set out to test the significance 
of those interactions using charge reversal mutagenesis with functional testing in 
Xenopus laevis oocytes expressing mutant receptors and G-proteins,   
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Figure 1.1 Major Classes of GPCRs with the Typical Binding Regions of Orthosteric 
Ligands. Class A (rhodopsin-like) GPCRs have a short extracellular N-terminus and an 
intracellular C terminus of variable length. Small ligands, such as biogenic amines, bind 
to a hydrophilic pocket within the transmembrane domain (TMD). Class B (Secretin 
family) agonist peptides simultaneously bind to the large extracellular N-terminal domain 
and the pocket between helices occupied in class A GPCRs by their small molecule 
ligands. Class C GPCRs differ from the others in that the N-terminus, in which the 
orthosteric binding site is located, is very long. (Stewart et al. 2012). 
  
  24 
 
 
Figure 1.2 G protein Activation Cycle. Ligand binding to the GPCR induces a 
conformational change in the receptor that is transduced to the Gα subunit increasing its 
affinity for GTP and promoting the exchange of GDP for GTP. The activated GTP-bound 
Gα subunit dissociates from the Gβγ subunits, whereupon both elements of the G-protein 
can regulate the activity of effector proteins. The cycle is terminated by hydrolysis of GTP 
to GDP, leading to the reassociation of the Gα and Gβγ subunits into the inactive 
heterotrimer complex (Rasmussen et al. 2011). 
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Table 1.1. G Protein Subunits and Their Primary Effectors. (Hermans 2003) 
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Figure 1.3 Pertussis Toxin-Mediated Uncoupling of Gαi/o Proteins from Their 
Cognate GPCRs. When the A-protomer of PTX penetrates into the host cells, the Gαi/o 
is ADP-ribosylated by the B-protomer resulting in inactivation of Gαi/o. Inhibition of the 
inhibitory effect of Gαi/o on adenylyl cyclase activity results in the elevation of intracellular 
cAMP levels, leading to activation of the cAMP-mediated signaling pathway (Vauquelin 
and Von Mentzer 2008).  
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Figure 1.4 Conformational heterogeneity of GPCRs and associated- signaling. 
Unliganded GPCRs exist in an equilibrium between multiple conformations (basal 
equilibrium). Agonists partially shift the equilibrium towards active conformations, 
whereas inverse agonists shift the equilibrium in the opposite direction. The different 
active conformations might be associated with variable degrees of activation of the same 
signaling pathway, or even associated with different signaling pathways (biased signaling) 
(Gurevich and Gurevich 2017).  
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Figure 1.5 Modes of action of allosteric modulators. A, An allosteric ligand binds to a 
site distinct from the orthosteric binding site and modulates the affinity (red) and/or 
efficacy (green) of the orthosteric ligand. Some allosteric ligands are capable of directly 
eliciting a response on their own (blue). B, Schematic representation of the various 
potential effects mediated by different allosteric ligands on the functional response of an 
orthosteric agonist. The first (solid red) is a positive allosteric modulator (PAM) that purely 
enhances orthosteric agonist affinity, as evidenced by an increase in potency (lower EC50) 
and leftward shift of the concentration-response curve compared to the orthosteric agonist 
alone (solid black). The second (solid green) is a PAM that purely enhances agonist 
efficacy, as evidenced by an increase in Emax and upward shift in its concentration-
response curve. The third (blue) demonstrates an allosteric agonist that modulates both 
the affinity and efficacy. The fourth (dashed red) is a negative allosteric modulator (NAM) 
that decreases the orthosteric agonist affinity, and thereby shifts its concentration-
response curve to the right. The fifth (dashed green) is a NAM that decreases the 
orthosteric agonist efficacy and causes a downward shift in the concentration-response 
curve (Ellaithy et al. 2015).  
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Figure 1.6 PAMs Maintain Temporal and Spatial Patterns of Native Receptor 
Signaling. A, 1)Endogenous agonist is released at locations where its effects are 
required. 2)Synthetic agonist is widely distributed and, thus can activate receptors 
throughout the body in locations where the signaling effects are not needed. 3)PAMs 
enhance the effects of endogenous agonists while still maintaining the spatial pattern of 
endogenous signaling (Burford, Traynor, and Alt 2015). B, A synthetic orthosteric agonist 
often produces a bigger effect than the endogenous agonist; however, its effects may 
decline with time as a result of receptor desensitization and/or downregulation. On the 
contrary, a PAM maintains the temporal pattern of endogenous signaling, and thus is less 
likely to cause receptor desensitization and/or downregulation (Ellaithy et al. 2015). 
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Figure 1.7 Outward Rotation of TM6 in Three class A GPCRs Upon Activation. Three 
class A GPCRs (beta-2 adrenergic, Muscarinic-2, and Mu-opioid receptors) captured in 
their crystallographic inactive and active conformations exhibit similar outward rotation of 
the intracellular end of TM6 (highlighted) upon activation, creating a G protein binding 
cavity on the cytoplasmic side (Latorraca, Venkatakrishnan, and Dror 2016). 
  
  31 
 
 
Figure 1.8 Disruption of the ionic lock in β2AR upon activation. (Kobilka and Deupi 
2007).  
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Figure 1.9 Secondary and tertiary tructures of Gα. A, Diagram of the secondary 
structure of Gα with α-helices represented as cylinders and β-sheets as arrows. Alpha 
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helical domain (AHD) is comprised of seven lettered α-helices (purple). Linkers 1 and 2 
(L1 and L2) connect the AHD with the Ras homology domain (RHD). The switch regions 
(orange) and receptor contact sites (pink) are highlighted. Regions involved in nucleotide 
binding are surrounded by red rectangles. Those are the TCAT motif in the β6–α5 loop 
opposite the receptor-binding C terminus on the α5 helix, and the phosphate-binding (P) 
loop connecting the β1 sheet to the α1 helix (Oldham and Hamm 2008). B, AHD is colored 
light brown and RHD is colored gray. Switch regions are colored in cyan. The P-loop is 
colored green, and loop regions involved in recognition and binding of GDP are colored 
in pink (Sprang 2016). 
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Figure 1.10 Glutamate Receptor Categories. A, Ionotropic glutamate receptors 
(iGluRs) are tetrameric ion channels (left) while metabotropic glutamate receptors 
(mGluRs) are dimeric GPCRs (right). Subunit heteromerization within different 
subfamilies further increases the functional diversity of iGluRs and mGluRs. (b) iGluRs 
and mGluRs are located both pre- and post-synaptically, where they are involved in 
different pathways of signal transmission, control of neurotransmitter release, and 
synaptic plasticity. In addition, mGluRs are located in extrasynaptic locations and glial 
cells, highlighting their regulatory functions (Reiner, Levitz, and Isacoff 2015). 
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Figure 1.11 Structural organization of mGluRs. Cartoon illustrating a full-length mGluR 
dimer. The large extracellular domain (ECD) consists of a bilobed ligand-binding domain 
(LBD), which contains the orthosteric i.e. glutamate binding site, and a cysteine-rich 
domain (CRD, which connects the LBD to the transmembrane domain (TMD). The TMD 
in turn contains the binding site(s) for allosteric ligands (Rondard and Pin 2015). 
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Figure 1.12 Classification and sequence homology dendrogram of mGluRs. 
(Muguruza, Meana, and Callado 2016).  
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Figure 1.13 Subunit Cooperativity in mGluR Activation. Model of occupancy-
dependent activation of mGlu2R, where LBD is either open (O) or closed (C) and the 
receptor is either resting (R) or active (A). Binding of agonist to one subunit in the dimer 
results in weak activation, while binding to both subunits results in 5x more activation 
(Levitz et al. 2016). 
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Figure 1.14 Chronic atypical antipsychotic therapy downregulates mGlu2R. 
Schematic model of the effect of chronic atypical antipsychotic treatment to the epigenetic 
status of the mGlu2R (Grm2) gene. A, Serotonin-induced activation of 5-HT2A receptor 
represses HDAC2 gene promoter activity in mouse and in human frontal cortex. B, 
Atypical antipsychotic drugs, such as clozapine, reverse the 5-HT2A receptor-dependent 
repression of HDAC2, an effect that is associated with increased HDAC2 promoter activity 
and repressive histone modifications at the mGlu2R promoter (Ellaithy et al. 2015).  
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Chapter 2 MATERIALS AND METHODS 
2.1 Computational Studies 
All computational studies were contributed by Dr. Yu Xu.  
2.1.1 Building an mGlu2R structural model 
A model of the mGlu2R truncated TM domain in the inactive state was constructed 
based on the mGlu5R crystal structure (PDB: 4OO9). The MODELLER program was 
used to generate an initial homology mGlu2R TM model. The Discovery Studio (DS) 3.5 
was used to further refine the model structure via energy minimization. 
2.1.2 Building mGlu2R-Gi protein complex model. 
Based on the β-2 adrenergic receptor-Gs protein complex (PDB:3SN6), a model of the 
mGlu2R-Gi protein complex was constructed. The truncated TMD mGlu2R model was 
used to replace the beta2 adrenergic receptor by Discovery Studio (DS) 3.5. The Gαs 
domain was also replaced by the Gαi crystal structure bound to GDP (PDB:4N0E). 
Previous research has shown that a Phe residue in ICL3 of mGluRs forms critical 
interactions with G alpha (Francesconi and Duvoisin 1998). Hence, we manually aligned 
the system to reduce the distance between mGlu2R F756 and Gαi W258 by 3Å. The 
whole system was then refined by energy minimization.     
2.1.3 Identifying allosteric modulators binding 
To accurately reproduce the geometry of the small ligand molecules, their structures 
were optimized by Gaussian 09. We then used AutoDock 4.2 to dock the PAM biphenyl-
indanone A (BINA) and the NAM Ro 64-5229 to the truncated mGlu2R model. The 
docking box (size: 18.75×18.75×18.75Å) was set around the extracellular side of the 
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receptor TM domain. By empirical free energy scoring, we selected 100 top docking 
configurations for each allosteric modulator. 
2.1.4 Molecular dynamics (MD) simulations and data analysis 
GROMACS v4.5.3 was used to conduct the simulation. The topology files of small 
molecules were calculated using the PRODRG web-server. The TMD structures of 
mGlu2R were immersed in an explicit phosphatidylcholine bilayer using the VMD 
package and solvated with SPC water molecules with 150 mM NaCl. Energy 
minimization and position-restrained MD runs were performed. The complexes were 
subjected to a 450 ns for truncated mGlu2R alone and 100ns for the  truncated mGlu2R 
with Gαi protein, runs that were deemed long enough to reach steady-state.  
The SIMULAID program was used to analyze/cluster structures, and to calculate 
interaction networks, including hydrogen bonds, salt bridges and hydrophobic contacts. 
2.2 Molecular Biology 
The following cDNAs used in the Xenopus oocyte heterologous expression system were 
subcloned into the pXOOM oocyte expression vector: human mGlu2R, all human 
mGlu2R mutants included in this study, pertussis toxin (PTX) subunit B, human Gαi1 
C351A (Gαi1*), and human Gαi1* mutants. The pGEMHE vector was used for human 
GIRK4-S143T (GIRK4*). Linearized and purified (Pure Link PCR Purification kit, 
Thermo Fisher Scientific) plasmids were transcribed in vitro using an mMESSAGE 
mMACHINE T7 Transcription kit (Thermo Fisher Scientific). Point mutations were 
introduced by Dr. Takeharu Kawano using standard Pfu-based mutagenesis techniques 
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according to the QuikChange protocol (Agilent Technologies), and verified by 
sequencing (Genewiz). 
2.3 Drugs and Chemicals  
L-glutamic acid was purchased from Sigma.  
2.4 Oocyte Preparation and Injection  
Oocytes from Xenopus laevis were surgically removed and subjected to collagenase 
treatment according to standard protocols (Fig. 2.1) (Logothetis et al. 1992; Hatcher-
Solis et al. 2014). Oocytes were then washed and incubated at 18 °C in an OR2 
solution with 2 mM Ca2+ and Penicillin/ Streptomycin antibiotics. Oocytes at stage V or 
VI of maturation were selected for microinjection of 1 ng of each cRNA, suspended in 
equal volumes (50 nL) of DEPC treated water. Injected oocytes were incubated for 
approximately 48 hours at 18 °C to allow for optimal protein expression. 
2.5 Two-Electrode Voltage-Clamp Recording and Analysis 
Whole-cell currents were measured by conventional two-electrode voltage clamp 
(TEVC) with a GeneClamp 500 amplifier (Axon Instruments, Union City, CA). A high-
potassium (HK) solution was used to superfuse cRNA-injected oocytes expressing the 
appropriate proteins to obtain a reversal potential for potassium (EK) of zero. The HK 
contained in millimolar (96 KCl, 1NaCl, 1 MgCl2, 5 KOH/HEPES, pH 7.4).  
Inwardly rectifying potassium currents through GIRK4* were obtained by clamping the 
cells at a voltage ramp from -80 to +80 mV. Basal GIRK4* currents were defined as the 
difference between inward currents obtained at -80 mV in HK and those obtained in the 
presence of 3mM BaCl2 in HK solution. Glutamate-induced currents were measured 
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respectively and normalized to basal current to compensate for size variability in 
oocytes. 
2.6 Statistics  
All data were expressed as mean ± standard error of the mean (SEM), unless otherwise 
indicated. Error bars in each figure represent SEM. For curve fitting, the following 
equation from Prism 6 software was used: Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-
X)*HillSlope)).Statistical significance between 2 groups was assessed using student’s t-
test. When multiple groups were analyzed, a one-way ANOVA followed by Tukey’s 
posthoc test was used (Prism 6). For all statistical analyses, significance was 
determined using p<0.05. Unless otherwise noted, all experiments were performed in at 
least two separate batches of oocytes. 
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Figure 2.1 The Xenopus oocyte heterologous expression system. Oocytes are 
isolated from Xenopus laevis frogs through a small abdominal incision and are 
subjected to mild collagenase treatment to detach them from the surrounding follicular 
cells. In vitro transcribed cRNA from a Xenopus vector (e.g. pXOOM) coding for the ion 
channel of interest (e.g. GIRK) is injected into the isolated oocytes. Two-electrode 
voltage clamp (TEVC) is utilized to record whole-cell currents, typically 2-3 days post-
injection (Hatcher-Solis et al. 2014).  
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Chapter 3 MAPPING THE INTRAMOLECULAR 
ELECTROSTATIC INTERACTIONS INVOLVED IN mGlu2R 
ACTIVATION 
3.1 Introduction 
Most GPCRs crystallized to date belong to the class A GPCRs, with no single full-length 
class C structure yet available. Moreover, the available crystal structures of truncated 
mGluR TMDs are bound by negative allosteric modulators (NAMs), and thus, represent 
receptor inactive states (Doré et al. 2014; Wu et al. 2014). Apart from the TM3-TM6 
ionic lock, very little data are available on the electrostatic interactions governing 
receptor activation.  
In this study, we embarked on an effort to characterize key intramolecular electrostatic 
interactions underlying the transition from the inactive to the active mGlu2R state, using 
an approach combining computational modeling, charge reversal mutagenesis, and 
functional testing using electrophysiology. Our preliminary computational predictions 
strongly suggested the presence of the TM3-TM6 ionic lock between K653 and E758. In 
addition, our predictions also led us to hypothesize that, upon breakage of the TM3-TM6 
ionic lock during activation, another intramolecular electrostatic interaction is 
established between K653 in TM3 and E754 in ICL3.  
In order to test this hypothesis, we employed our well-established assay of GPCR Gi 
activity (Fig. 3.1) (Fribourg et al. 2011; Hatcher-Solis et al. 2014). Xenopus laevis 
oocytes can be utilized as a heterologous system to express mGlu2R, together with G-
protein Inwardly Rectifier Potassium 4 star (GIRK4*) channel which can serve as a 
reporter for receptor Gi signaling. Two days following cRNA injection, two-electrode 
voltage-clamp (TEVC) recordings can be performed using a voltage-ramp protocol from 
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-80 mV to +80 mV. Recordings are performed in High K+ aqueous solution that is 
perfused into the chamber and allows for administration of glutamate to study receptor 
activation. Glutamate-induced activation of mGlu2R results in liberation of the beta 
gamma subunits (Gβγ) from the G protein heterotrimer. Gβγ can then bind to a cleft 
formed by cytosolic loops of adjacent subunits of GIRK4*, potentiating its current 
(Mahajan et al. 2013), offering a quantitative readout for receptor function.  
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3.2 Results 
3.2.1 Creating a structural model of mGlu2R 
Using the available crystal structure of mGlu5R TMD (Doré et al. 2014), a monomeric 
truncated model of mGlu2R was created (Fig. 3.1). 450 nanoseconds molecular 
dynamics (MD) simulations were performed on both unliganded-receptor and receptor 
bound to either biphenyl-indanone A (BINA; an mGlu2R PAM) or Ro 64-5229 (an 
mGlu2R NAM) (Fig. 3.2). When the system was deemed stable after the first 200 
nanoseconds, 500 snapshots were taken during the remainder of the MD run at a rate 
of 2 per ns. During this window, the frequency of formation of three prominent salt 
bridges that stood out were monitored: K653-E758 (TM3-TM6), K653-E754 (TM3-ICL3), 
and E758-K813 (TM6-TM7) (Fig. 3.3). A pattern of salt bridge formation was noticed, 
whereby the unliganded and NAM systems were comparable and in contrast with the 
PAM system. The two salt bridges K653-E758 and E758-K813 are stabilized in the 
receptor alone or 64-5229 (inactive) systems but broken in the BINA (active) system. It 
is worth mentioning that the first of those two pairs correspond to the TM3-TM6 ionic 
lock i.e. K3.50-E6.35. The opposite pattern is observed for the salt bridge K653-E754 
which it is established upon activation (Fig. 3.4). To test these predictions, we resorted 
to our well established TEVC functional assay in oocytes to test the effects of mutations 
that reverse the charges of residues involved in these potential intramolecular 
electrostatic interactions.  
3.2.2. Single mutants of the TM3-TM6 salt bridge disrupt while the double 
mutant rescues receptor activation  
  47 
We tested the Gi responses of both the single mutants K653E and E758K as well as the 
double mutant K653E-E758K upon glutamate application. Glutamate concentration-
response curves were compared between mutants and in relation to WT. It is worth 
noting here that in order to test the interactions of mGlu2R with different Gαi mutants in 
later experiments (see next chapter), any endogenous Gαi signaling had to be inhibited. 
To achieve that, experiments throughout this study, including the ones mentioned here, 
have been conducted in the presence of pertussis toxin subunit B (PTX), which inhibits 
Gi signaling (Fig. 3.5). Receptor was instead allowed to signal by co-expressing the 
PTX-insensitive Gαi1 mutant C351A (or Gαi1*) (Rusinova, Mirshahi, and Logothetis 
2007). 
Fig. 3.6 shows that Gi activity was completely abolished in the single mutant E758K and 
signifcantly decreased in K653E, but interestingly, partially rescued in the double mutant 
K653E-E758K. The efficacy of glutamate (Emax) and its potency (pEC50) on different 
mutants are summarized in Table 3.1. Although the pEC50 in the double mutant was 
not different than in WT, the Emax remained significantly lower than that of WT. The 
partial, rather than complete, rescue of the Emax in the double mutant can be due to 
either reduction in surface expression level or disruption of other important interactions 
in the vicinity of the ionic lock. 
3.2.3. Single mutants of the TM6-TM7 salt bridge disrupt receptor 
activation but the double mutation fails to rescue receptor activation 
Although both residues in the TM6-TM7 salt bridge network showed decreased 
responses to glutamate upon charge substitution (partial reduction in K813E and 
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complete absence of responses in E758K), swapping the two charges across the pair 
via the double mutation failed to rescue Gi responses to glutamate (Fig. 3.7). 
3.2.4. Role of TM3-ICL3 electrostatic interactions in receptor activation  
Our computational results predict that shifting from the receptor inactive state to the 
activated state changes the pattern of salt bridges formed in the TMD.  Namely, the 
TM3-TM6 (K653E-E758K), that predominates in the inactive state, is broken and 
another salt bridge (TM3-ICL3) stabilizes the active state (Fig. 3.3). Since the residue 
K653 (K3.50) is involved in both salt bridges, we predicted that the major change 
occurring during activation is a relative movement of TM3 and ICL3 towards each other, 
and of TM3 and TM6 away from each other.  
To test this hypothesis, we characterized the ICL3 mutant E754K that displayed an 
interesting phenotype; a left-ward shift in its glutamate concentration response curve 
compared to WT (Fig. 3.8). Although the Emax was reduced, the significantly enhanced 
pEC50 (Table 3.2) strongly suggests a role for ICL3 in receptor activation. Interestingly, 
the double mutant K653E-E754K rescued the Gi activation compared to K653E with a 
pEC50 not significantly different from WT. Reestablishing the entire TM6-TM3-ICL3 salt 
bridge network had a similar effect. All E754K mutants (single, double, and triple) had a 
lower Emax than glutamate despite the pEC50 being either enhanced or comparable to 
WT. This could be due to a reduction in surface expression levels.    
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3.3. Discussion 
Our interpretations of the mutation-associated shifts in the agonist concentration 
response curves assume changes in receptor basal activity (activity in the absence of 
agonist given that the ionic lock mutants are expected to destabilize an inactive receptor 
conformation). This could explain how the E758K mutant did not display any response 
to glutamate, possibly due to a high constitutive activity that does not leave a 
measurable range for agonist-induced current activation. On the other end of the 
spectrum, the ICL3 mutant E754K was associated with the highest potency for 
glutamate, indicating the widest range of receptor activation likely because the mutant 
stabilizes an active receptor conformation.  
Based on these interpretations, it is fair to say that a limitation of our experiments is that 
they do not test the effects of the mutations on the basal activity of the receptor. A main 
hurdle is the large variability in basal currents of the reporter channel in TEVC. To 
circumvent this challenge, we have considered FRET-based approaches of assaying 
receptor constitutive activity (Levitz et al. 2016). We anticipate that the TM6 mutant 
E758K would display the highest basal activity, whereas the ICL3 mutant E754K may 
show no change or lower basal activity compared to control. 
Another caveat is that the oocyte results do not exclude differences in surface 
expression to contribute to the functional changes we see in mutants. However, the 
changes in glutamate potency as well as the rescue effects in the double mutants 
suggest changes in function rather than just in expression.     
Previous evidence implicated TM3 in stabilizing the receptor in the inactive state. Our 
work expands on the critical role of TM3 to also include a role in stabilizing the activated 
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state, by extending the interaction with the intracellular end of TM6 to the ICL3. These 
two patterns of salt bridge formation correspond to two functional states of the receptor; 
inactive and active.  
Although the TM3-TM6 ionic lock interaction has been revealed in multiple GPCR 
structures (Vogel et al. 2008; Palczewski et al. 2000; Wang et al. 2018; Rasmussen et 
al. 2007), to our knowledge, no previous active state GPCR structures have captured 
the relative movement of TM3 and ICL3 towards each other with the establishment of a 
new salt bridge pattern for TM3 in the active state replacing the inactive state-
associated ionic lock with TM6. A potential reason to explain missing this important 
interaction is the fact that the high flexibility and length of ICL3 preclude the formation of 
ordered protein crystals. Thus, in most currently available active structures ICL3 has 
been substituted by a fusion partner (Rasmussen et al. 2011; Huang, Manglik, et al. 
2015; Kruse et al. 2013).  
Other studies have also suggested a key role for ICL3 in interaction with G-protein 
(Francesconi and Duvoisin 1998). Our study reveals a role in GPCR activation as well. 
We discuss in the next chapter how same negative charge in ICL3 (E754) does not only 
engage in electrostatic interactions with the receptor TMD, but also with a positive 
charge at the opposing interface of Gα subunit.  
In summary, our results indicate that the prevailing salt bridge interaction in the inactive 
state is the one between TM3 and TM6, consistent with many previous studies. During 
activation, TM3 breaks its interaction with TM6 and engages in a different salt bridge 
pattern with ICL3, a region that likely also plays a role in subsequent G-protein 
activation and is key to understanding the structural basis of interaction between 
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GPCRs and intracellular partners. Figure 3.9 illustrates conformational changes upon 
activation by comparing mGlu2R in unbound, Ro 64-5229-, and BINA-bound states.  It 
can be seen that most of the changes between the simulated inactive and active states 
of mGlu2R appear in the intracellular loops, ICL3 and ICL2.  Studying surface 
expression as well as basal activity of the aforementioned mutants remains of 
paramount importance to further test our interpretations.   
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Figure 3.1 Structural model of mGlu2R TMD. The initial structural model of mGlu2R in 
truncated form during MD simulations. mGlu2R (purple ribbons) embedded in lipids (blue 
wires), with water molecules (red) and Na+ ions (green spheres). 
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Figure 3.2 Monitoring root-mean-square-deviation (RMSD) of the alpha carbons 
over a 450 nanoseconds MD run. RMSD of Cα atoms during MD simulations for the 
truncated mGlu2R alone, with BINA, and with Ro 64-5229 binding (gray, red, and purple 
traces, respectively). 
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Figure 3.3 Comparison of the patterns of salt bridges formed between 200 and 450 
nanoseconds of MD runs. Compared to the alone and the Ro 64-5229 systems, BINA 
causes breakage K653-E758 and E758-K813 salt bridges, and instead, an increased 
interaction between K653 and E754. 
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Figure 3.4 Zoomed-in views of the intracellular side of the receptor models in the 
active and inactive states. Snapshots of truncated mGlu2R in the presence of BINA 
(upper) or Ro 64-5229 (lower) show the competition between E758 (in TM6) and E754 
(in ICL3) to interact with K653 (in TM3). Binding of BINA disrupts the ionic lock, and 
increase the interaction between K653 and E754. 
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Figure 3.5 mGlu2R functional assay in Xenopus oocytes. A, Simple schematic of 
mGlu2R-induced Gi-dependent GIRK4* activation assay (Fribourg et al. 2011). B, A 
sample recording from an oocyte injected with G4*+mGlu2R RNA. C, A sample 
recording from an oocyte injected with G4*+mGluR2+PTX-S1 RNA. D, A sample 
recording from an oocyte injected with G4*+mGluR2+PTX+Gαi1 C351A (Gαi*) RNA.   
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Figure 3.6 Effect of charge reversal mutations in the K653-E758 ionic lock 
between TM3 and TM6. No glutamate response was detected in the mutant E758K, 
and the mutant K653E exhibited a marked reduction in glutamate effect as evident by 
both a rightward and downward shift in glutamate concentration response curve. The 
effect was partially rescued when the ionic lock interaction was reestablished in the 
double mutant K653E-E758K (n≥6 per condition, experiments were performed in ≥2 
batches of oocytes except for E758K where n=4 from one batch).  
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Table 3.1. Summary of glutamate effects on the TM3-TM6 ionic lock mutants. 
 pEC50 Emax 
WT 5.91 ± 0.049 101.50 ± 3.759 
K653E 5.48 ± 0.156* 27.32 ± 4.011* 
E758K ND ND 
K653E-E758K 6.10 ± 0.288† 49.26 ± 8.669*† 
N.D. no response detected 
* p-value < 0.05 when compared to WT 
† p-value < 0.05 when compared to K653E 
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Figure 3.7 Effect of charge reversal mutations in the E758-K813 salt bridge 
between TM6 and TM7. The TM7 mutant K813E showed a rightward and downward in 
response to glutamate. On the other hand, no glutamate response was detected in the 
mutant E758K. The double mutant also did not show any response to glutamate (n≥6 
per condition, experiments were performed in ≥2 batches of oocytes except for E758K 
where n=4 from one batch).  
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Figure 3.8 Effect of charge reversal mutations in the TM3-ICL3 salt bridge. The 
ICL3 mutant E754K displays an enhanced response to glutamate. The double mutant 
K653E-E754K rescues the Gi responses compared to the single mutant K653E and 
shows a comparable potency to that of WT. The triple mutant K653E-E754K-E758K 
shows similar effects to the double mutant, despite a lower Emax (n≥6 per condition, 
experiments were performed in ≥2 batches of oocytes) 
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Table 3.2. Summary of glutamate effects on the TM3-ICL3 salt bridge mutants. 
 pEC50 Emax 
WT 5.91 ± 0.049 101.50 ± 3.759 
K653E 5.48 ± 0.156* 27.32 ± 4.011* 
E754K 6.41 ± 0.0784* 71.25 ± 3.645* 
K653E-E754K 6.09 ± 0.112† 63.93 ± 5.738*† 
K653E-E754K-E758K 6.20 ± 0.098† 34.84 ± 2.424* 
* p-value < 0.05 when compared to WT 
† p-value < 0.05 when compared to K653E 
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Figure 3.9 Conformational changes of mGlu2R upon activation. A, Superimposed 
truncated mGlu2R structural models in in unbound (gray), NAM-bound (red), and PAM-
bound (green) states. B, Zoomed in view of the intracellular end of TMD, ICL2, and 
ICL3. The most prominent changes are separation of TM3 and TM6, Outward 
movement of the intracellular end of TM6, and upward movement of ICL3 towards TM3. 
C, Same structures, viewed from the intracellular side. 
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Chapter 4 MAPPING THE INTERMOLECULAR 
ELECTROSTATIC INTERACTIONS BETWEEN mGlu2R AND 
THE Gαi SUBUNIT 
4.1 Introduction 
Activation of a GPCR involves conformational changes that trigger interaction with a 
specific G- protein. Despite the wealth of structural information from GPCR studies, a 
major unsolved question is the structural basis by which a receptor catalyzes nucleotide 
exchange in G proteins. After we revealed a critical role for certain electrostatic 
interactions in receptor activation, we asked the question: are there key electrostatic 
interactions involved in receptor-induced G-protein activation?  
The electrostatic properties of the Gα subunits, which in some cases differ greatly not 
only between families but also between subfamilies suggest that electrostatic 
complementarity may be an important factor in receptor-G-protein coupling selectivity 
and/or receptor-mediated G protein activation (Baltoumas, Theodoropoulou, and 
Hamodrakas 2013).  
In this chapter, we test for critical electrostatic interactions involved in receptor-mediated 
Gαi activation and, by revealing key intermolecular electrostatic interactions, add to the 
previous literature suggesting important roles for intracellular loops 2 and 3 (ICL2 and 
ICL3) in receptor interactions with G-protein (Ulloa-Aguirre et al. 2007; Rasmussen et 
al. 2011). To test computational predictions, we again employed charge reversal 
mutagenesis and TEVC in Xenopus laevis oocytes. Importantly, all Gαi mutations tested 
were introduced in the background of the PTX-insensitive Gαi mutant (Gαi1 C351A) 
(Rusinova, Mirshahi, and Logothetis 2007). 
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4.2 Results 
4.2.1 Structural modeling of mGlu2R with Gαi  
Based on the β-2 adrenergic receptor—Gs protein complex (PDB:3SN6), we built the 
mGlu2R—Gi protein complex (Fig. 4.1). The truncated mGlu2R model we previously 
built was used to replace the β-2 adrenergic receptor. The Gαs domain was also 
replaced by the Gαi crystal structure with GDP bound (PDB:4N0E) (Thaker et al. 2014).  
100 nanoseconds molecular dynamics (MD) simulations were performed on both 
unliganded-receptor and receptor bound to either BINA or Ro 64-5229. Predicted 
intermolecular electrostatic interactions between receptor and G-protein are 
summarized in Fig. 4.2. To test these predictions experimentally, we resorted again to 
TEVC experiments. 
4.2.2 mGlu2R residues critical for the interaction with Gα tend to be located 
in or adjacent to intracellular loops 2 and 3 
Our computational studies suggested that six charged residues towards the cytoplasmic 
side of mGlu2R form key salt bridges with Gα. Three of those residues are located in 
regions that are thought to play key roles in interaction with the receptor; R670 and 
R672 in ICL2, and E754 in ICL3. The other 3 residues are located in TMD very close to 
intracellular loops; K653 and R656 in TM3, and K760 in TM6.  
We proceeded to screen the effects of mutating each of these residues, apart from 
mutations of K653 and E754 which have already been characterized in chapter 3. Fig. 
4.3 demonstrates that all four mutants tested showed attenuated responses to 
glutamate-induced activation compared to WT. In order to determine which of these six 
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residues play critical roles in interactions with G-protein, we proceeded to test the Gα 
residues predicted to form salt bridges with the aforementioned mGlu2R residues.  
4.2.3 Gα residues that seem critical for the interaction with the receptor 
tend to be facing intracellular loops 2 and 3 of the receptor 
According to the model, eight residues in the Gα Ras homology domain (AHD) are 
engaging in intermolecular salt bridges with the previously tested six residues of 
mGlu2R. After screening all eight mutants (Fig. 4.5), three behaved significantly 
different from control Gαi* in response to glutamate activation. Notably, these residues 
are located in close proximity to the two residues of mGlu2R that the model predicts to 
engage in the largest number of intermolecular electrostatic interactions (Fig. 4.6). 
Namely, Gαi residue K317 is interacting with E754 in ICL3 of mGlu2R — a residue that 
we have shown to be key in receptor activation. Furthermore, Gαi residues E33 and 
D193 are both competing to interact with residue R670 in ICL2 of mGlu2R.  
4.2.4 mGlu2R third intracellular loop interaction with Gα protein  
We started by mGlu2R residue E754 in ICL3, which we have shown in chapter 3 to be 
critical in receptor activation through its intramolecular electrostatic interactions, mainly 
with K653 in TM3. Our computational results predicted an interaction of mGlu2R E754 
with K317 in the α4-β6 linker of Gα; an interaction that is stabilized in the active state. 
Thus, we wanted to test glutamate responses of cells co-expressing these two mutants 
together (Fig. 4.7).  
Gαi* K317E mutant has an attenuated response to glutamate as evident by the Emax 
being significantly lower than in control Gαi* (Table 4.1). Although the potency reduction 
was not statistically significant, co-expressing the mGlu2R mutant E754K significantly 
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increased the potency. Taken together, computational and experimental results support 
a critical role of ICL3, mediated by its negatively charged residue 754, in receptor-
induced G-protein activation.   
4.2.5 mGlu2R second intracellular loop interaction with Gα protein  
According to the computational predictions, interaction of E33 with receptor ICL2 is 
stabilized in the active state, whereas that of D193 is stabilized in the inactive state (Fig. 
4.3A). Experimental results supported this hypothesis (Fig. 4.3B) since mutating E33 
interfered with mGlu2R-induced G protein activation, presumably since the mutation 
strengthened Gαi D193 interaction with mGlu2R R670. Mutating D193, on the other 
hand, enhanced activation indicating a stronger R670—E33 intermolecular active state 
interaction.  
Residue E33 is located in the N-terminal helix-β1 (αN–β1) linker while D193 is located 
in the β2-β3 linker of Gαi (Fig. 4.4). Both residues are located in close proximity to each 
other and to mGlu2R R670 in ICL2.  
We first wanted to answer the question if mutating the two residues, E33 and D193, 
simultaneously destabilizes the two salt bridges with ICL2, and thus ultimately restore 
the control level of receptor—G-protein signaling (Fig. 4.8A). Although the potency of 
glutamate did not significantly differ among all four G alphas, the efficacy was different 
with E33R showing significantly reduced responses, and the double mutant behaving in 
a manner comparable to control (Fig. 4.8B) (Table 4.2).  
Next, we tested whether reestablishing the overall R670 (ICL2)—Gα salt bridge network 
can restore receptor-mediated G-protein activation to WT levels. Fig. 4.9 and Table 4.3 
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illustrate that when the 3 mutations are co-present, glutamate responses are mostly 
similar WT levels, and different from R760D(E).  
To zoom in on the intermolecular electrostatic interaction between R670 and D193, we 
tested the effects of co-mutating both proteins at these residues. Fig. 4.10 and Table 
4.4  show that, although the potency of glutamate in the mGlu2R mutant was 
significantly different from control, the combined mutants did not. Moreover, the 
combined mutants were associated with a significantly higher Emax than when only 
mGlu2R was mutated.  
Finally, we focused on the other side of the receptor ICL2—Gα salt bridge network i.e. 
the electrostatic interaction between R670 and E33. Fig. 4.11 and Table 4.5  show that, 
in contrary to the case with D193, co-mutating both proteins at these residues failed to 
rescue the responses to glutamate.   
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4.3 Discussion 
In this chapter, we tested our computational predictions regarding intermolecular 
electrostatic interactions between mGlu2R and Gαi. Effects of all mutations in predicted 
mGlu2R residues supported the model since they attenuated glutamate responses 
compared to in WT. Intracellular loop 3 residue E754, which we have shown in chapter 
3 to be critical for agonist-induced receptor activation, seems to also be key for 
receptor-mediated Gα protein activation, thus functioning as a major hub for mGlu2R 
intramolecular as well as intermolecular electrostatic interactions with G-protein.  
Mutations in Gαi, on the other hand, did not all alter glutamate-induced activation. This 
is not surprising considering that the model predicts each of the tested mGlu2R 
residues to engage in salt bridges with multiple Gα residues, but those of Gα mostly 
form single intermolecular salt bridges the mutation of which might not be enough to 
alter glutamate activation. This may also explain why single residue mutations in the Gα 
C-terminus (D341R, K349E, D350K, and D350R), a region known to be physically 
engaged by the activated receptor, did not alter glutamate activation.  
The two Gα residues that proved to engage in key intermolecular electrostatic 
interactions associated with activation, E33 and K317, are located in Gα regions known 
to contact the receptor; αN–β1 loop and α4–β6 linker, respectively (Fig. 4.4). 
Concomitant ICL2- and ICL3-mediated conformational changes in these linkers are 
likely transmitted to β1-α1 and β6–α5 loops, which coordinate the nucleotide, thus 
cooperatively facilitating nucleotide release.  
Although previous research has shown the involvement of αN-β1 and α2-α3 linkers, 
which contain E33 and D193 respectively, in receptor mediated-activation of Gα 
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(Huang, Sun, et al. 2015; Rasmussen et al. 2011), our finding that the competition 
between negatively charged residues within these 2 linkers for the positively charged 
ICL2 to stabilize opposite states is novel. Destabilizing one interaction favors the other, 
and simultaneously destabilizing both restores a balanced signaling. Although charge 
swapping between ICL2 and D193 supports this idea, the analogous experiment for E33 
failed to support this notion. Reasons that might underlie the lack of rescue for E33 
could be alterations in expression levels or cumulative effects of mutations that could 
also be disrupting several other interactions that were not addressed.  
In summary, our results add to the results from chapter 3 and indicate a key role for 
electrostatic interactions, especially those involving ICL2 and ICL3, in mGlu2R- 
mediated conformational changes in Gα required for activation.    
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Figure 4.1 Structural model of truncated mGlu2R — G-protein complex. Truncated 
mGlu2R (blue ribbons), GDP-bound Gα (yellow), Gβ (purple), and Gγ (green). 
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Figure 4.2 Schematic cartoon of potential electrostatic interactions within 
mGlu2R — G-protein complex. Circles represent residues predicted to form salt 
bridges, while the connecting lines represent potential electrostatic interactions. Red 
lines indicate interactions that are stabilized in the inactive state, whereas green lines 
are ones stabilized in the active state.  
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Figure 4.3 mGlu2R residues potentially critical for the interaction with Gα tend to 
be located in or adjacent to intracellular loops 2 and 3. A, mGlu2R residues 
potentially critical for intermolecular interactions with Gα are represented by circles. 
Residues that are also involved in intramolecular electrostatic interactions are colored 
gray. All other residues are colored blue. B—E, dose response curves of R656D, 
R670E(D), R772E, and K760D (n≥6 per condition, experiments were performed in ≥2 
batches of oocytes).  
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Figure 4.4 Gα residues predicted to engage in key electrostatic interactions with 
mGlu2R. Diagram of the secondary structure of Gα with α-helices represented as 
cylinders and β-sheets as arrows. Residues predicted by computational studies to be 
engaging in key intermolecular electrostatic interactions with the receptor are 
represented by yellow circles in the Ras homology domain (RHD) (Oldham and Hamm 
2008).   
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Figure 4.5 Effects of mutations in Gα residues proposed by computational 
modeling as candidates for key intermolecular electrostatic interactions. All 
mutations of Gα were introduced in the background of the PTX-insensitive mutant (Gαi*) 
(n≥6 per condition, experiments were performed in ≥2 batches of oocytes). Only 
mutants significantly different from control (A, B) are colored.  
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Figure 4.6 Residues involved in intermolecular electrostatic interactions at the 
mGlu2R — Gαi interface. A, Structural model of mGlu2R—Gαi complex with residues 
involved in intermolecular electrostatic interactions labeled and shown as CPK spheres. 
B, Gα residues E33 and D193 are competing to interact with residue R670 in ICL2 of 
mGlu2R. Interaction of E33 with receptor ICL2 is stabilized in the BINA (active) state, 
whereas that of D193 is stabilized in the Ro64 (inactive state). C, E754 in ICL3 of 
mGlu2R interacts with Gα residue K317 only in the active system. 
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Figure 4.7 mGlu2R intracellular loop 3 interaction with Gα K317 in α4-β6 linker. 
Co-expressing mGlu2R and Gαi* mutants E754K and K317E, respectively, rescues 
K317E responses to glutamate (n≥6 per condition, experiments were performed in ≥2 
batches of oocytes). 
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Table 4.1. Summary of the effects of mutations in mGlu2R ICL3—Gαi on 
glutamate responses. 
 pEC50 Emax 
mGlu2R WT + Gαi* control 5.64 ± 0.054 103.4 ± 5.031 
mGlu2R E754K + Gαi* control 6.26 ± 0.129* 98.13 ± 8.571 
mGlu2R WT + Gαi* K317E 5.50 ± 0.027 72.03 ± 3.194* 
mGlu2R E754K + Gαi* K317E 6.08 ± 0.111*† 90.21 ± 7.918 
* p-value < 0.05 when compared to mGlu2R WT + Gαi* control,  
† p-value < 0.05 when compared to mGlu2R WT + Gαi* K317E 
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Figure 4.8 Simultaneously destabilizing Gαi E33 and D193 interactions with ICL2 
restores control levels of activation.  A, a schematic cartoon of the competition 
between E33 and D193 of Gαi to engage in salt bridges with ICL2 of mGlu2R and 
stabilize opposite states (red; inactive, and green;active). B, Glutamate dose response 
curves for single vs. double mutants (n≥6 per condition, experiments were performed in 
≥2 batches of oocytes). 
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Table 4.2. Summary of glutamate reponses in single and double mutants of Gαi* 
residues interacting with receptor ICL2. 
 pEC50 Emax 
control 5.94 ± 0.121 101.40 ± 13.710 
E33R 5.73 ± 0.701 35.73 ± 18.970* 
D193R 6.21 ± 0.129 143.90 ± 14.250† 
E33R/D193R 6.07± 0.167 125.10 ± 17.400† 
* p-value < 0.05 compared to control 
† p-value < 0.05 compared to E33R 
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Figure 4.9 Reestablishing the overall  mGlu2R R670 — Gαi1 E33/D193 Salt Bridge 
Network. Co-mutating both Gα residues restores control levels of glutamate responses 
(n≥6 per condition, experiments were performed in ≥2 batches of oocytes).  
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Table 4.3. Summary of the effect of reestablishing the salt bridge network for 
residue R670 in ICL2 of mGlu2R. 
 pEC50 Emax 
mGlu2R WT + Gαi* control 6.06 ± 0.103 105.20 ± 7.979 
mGlu2R R670D + Gαi* control 5.57 ± 0.099** 87.43 ± 9.787 
mGlu2R R670E + Gαi* control 5.52 ± 0.077** 95.16 ± 7.723 
mGlu2R R670D + Gαi* E33R/D193R 5.67 ± 0.067 132.70 ± 15.090 
mGlu2R R670E + Gαi* E33R/D193R 5.62± 0.139* 131.40 ± 7.682† 
* p-value < 0.05 when compared to mGlu2R WT + Gαi* control,  
** p-value < 0.01 when compared to mGlu2R WT + Gαi* control,  
† p-value < 0.05 when compared to mGlu2R R670E + Gαi* control 
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Figure 4.10 Effects of mutations in mGlu2R ICL2—Gαi D193 salt bridge. Co-
mutating mGlu2R ICL2 and Gαi D193 restores control level of responses to glutamate 
activation (n≥6 per condition, experiments were performed in ≥2 batches of oocytes). 
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Table 4.4. Summary of the effects of mutations in mGlu2R ICL2—Gαi D193 on 
glutamate responses. 
 pEC50 Emax 
mGlu2R WT + Gαi* control 5.98 ± 0.092 104.60 ± 7.093 
mGlu2R R670D + Gαi* control 5.49 ± 0.072* 82.74 ± 6.761 
mGlu2R WT + Gαi* D193R 6.23 ± 0.122 140.80 ± 12.060* 
mGlu2R R670D + Gαi* D193R 5.74 ± 0.079 126.60 ± 8.233† 
* p-value < 0.05 when compared to mGlu2R WT + Gαi* control,  
† p-value < 0.05 when compared to mGlu2R R670D + Gαi* control 
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Figure 4.11 Effects of mutations in mGlu2R ICL2—Gαi E33 salt bridge. Co-mutating 
mGlu2R ICL2 and Gαi E33 failed to restore control level of responses to glutamate 
activation (n≥6 per condition, experiments were performed in ≥2 batches of oocytes). 
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Table 4.5. Summary of the effects of mutations in mGlu2R ICL2—Gαi E33 on 
glutamate responses. 
 pEC50 Emax 
mGlu2R WT + Gαi* control 5.70 ± 0.069 103.80 ± 5.811 
mGlu2R R670E + Gαi* control 5.44 ± 0.119 73.58 ± 9.823 
mGlu2R WT + Gαi* E33R 5.91 ± 0.069 30.98 ± 9.050* 
mGlu2R R670E + Gαi* E33R 5.45 ± 0.082 16.53 ± 1.569* 
* p-value < 0.05 when compared to mGlu2R WT + Gαi* control 
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Chapter 5 CONCLUDING REMARKS 
Three potential limitations are worth considering regarding the mGlu2R structural model 
used for our computational studies, which make it more similar to class A GPCRs. First, 
the receptor structure is truncated i.e. misses the entire N-terminal ECD that contains 
the glutamate binding site. Second, a PAM (BINA) structure rather than glutamate was 
docked into the receptor structure to study activation. Third, the structure is a monomer 
rather than a dimer of two mGlu2R subunits. Nevertheless, experimental data from this 
study supported a large number of predictions from the model, and thus, provided 
experimental validation for our model as a surrogate for glutamate-induced activation of 
the full-length dimeric receptor.  
Table 5.1. summarizes the results of charge swapping between residues potentially 
engaging in key salt bridges that we tested. Briefly, we elucidated in chapter 3 the role 
of intermolecular electrostatic interactions in mGlu2R activation. First, we showed that 
similar to a large number of GPCRs, a TM3-TM6 ionic lock functions in mGlu2R to 
stabilize the receptor in an inactive state. We then revealed a critical role for ICL3 by 
which it replaces TM6 in electrostatically interacting with TM3 in order to stabilize the 
active state. An advantage of our theoretical computational approach is its dynamic 
nature, allowing us to reveal a novel role for ICL3 in intermolecular receptor activation, 
as opposed to the static nature of experimental structural approaches like X-ray 
crystallography and cryo-electron microscopy. 
Full-length, glutamate-bound and/or dimeric receptor models are currently limited by 
technical challenges but will likely be easier to build in the future. In order for a better 
understanding of receptor activation, it might be important to probe any potential 
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intermolecular salt bridges between ICL2 and ICL3 that allows both loops to interact 
with each other before they both relay activation to G-protein. Whether critical mGlu2R 
residues such as E754 (ICL3) are conserved in distant GPCRs and play analogous 
roles remains to be tested. 
In chapter 4, we tackled the role of intermolecular electrostatic interactions in 
communication of activation from the receptor to Gα. We reveal critical roles for three 
charged residues, all located in regions that contact the receptor, in stabilizing different 
states of receptor-G-protein interactions. Two of those, E33 in the N-terminal helix-β1 
linker and D193 in β2-β3 linker, are competing for R670 in ICL2. The R670-D193 salt 
bridge stabilizes the inactive state, whereas R670-E33 stabilizes the active state. By 
mutating one residue, its salt bridge is destabilized allowing the competing residue’s salt 
bridge to more strongly interact with the receptor’s ICL2, favoring its inactive/active 
state. The third residue we identified is K317 in α4-β6 linker which interacts with the 
residue E754 in ICL3. The locations of E33 and K317 within Gα may explain their roles 
in G-protein activation. Their respective and concomitant engagement by the receptor’s 
ICL2 and ICL3 might induce structural rearrangement of the β1-α1 (P-) and β6–α5 
loops, which coordinate the phosphate and the purine of the nucleotide respectively, 
allowing nucleotide release. This is consistent with the current notion that allosteric 
communication between the receptor—G-protein interface and the nucleotide binding 
site involves the cooperative actions of different pathways that simultaneously 
destabilize the phosphate and the guanine of the nucleotide ensuring efficient GDP 
release (Hilger, Masureel, and Kobilka 2018).    
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Taken together with results from chapter 3, it appears that residue E754 allows ICL3 to 
act as a major hub on which receptor activation converges and is relayed to G-protein.  
The lack of appreciable effects of mutations of Gα residues, also located in regions that 
contact the receptor, does not exclude a role these residues may play in electrostatically 
interacting with the receptor intracellular loops. Such roles could be revealed by testing 
double or triple mutants such as D341R/K349E/D350R.  
Lastly, testing the effects of mutations on receptor surface expression as well as basal 
receptor-G-protein signaling remains an important goal for a more complete 
experimental characterization and understanding of the disruption and rescue of the 
predicted electrostatic interactions. 
Our study that utilized a dynamic approach for studying mGlu2R signaling combining 
MD simulations with functional studies of receptor and G-protein mutants can serve as a 
prototype for studying the role of electrostatic interactions in other GPCRs. Additional 
intermolecular interactions that can be explored in the future using this approach include 
receptor interactions with Gβγ and other GPCR-interacting partners such as arrestins, 
Gα—Gβγ interactions, and ultimately, G-protein interactions with downstream effectors.  
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Table 5.1. Summary of the salt bridge interactions tested. 
Regions Involved Residues 
Involved 
Receptor State in 
Which the Interaction 
Is Stabilized 
Effect of Charge 
Swapping on 
Glutamate-induced 
Gi Activation 
mGlu2R intramolecular electrostatic interactions 
TM3 — TM6 K653 — E758 Inactive Rescue 
TM6 — TM7 E758 — K813 Inactive No rescue 
TM3 — ICL3 K653 — E754 Active Rescue 
mGlu2R — Gα intermolecular electrostatic interactions 
ICL3 — α4-β6 linker E754 — K317 Active Rescue 
ICL2 — N-terminal 
helix-β1 linker 
R670 — E33 Active Rescue 
ICL2 — β2-β3 linker R670 — D193 Inactive Rescue 
 
 
 
  
  91 
Literature cited 
Alewijnse, Astrid E, Henk Timmerman, Edwin H Jacobs, Martine J Smit, Edwin Roovers, Susanna 
Cotecchia, and Rob Leurs. 2000. 'The Effect of Mutations in the DRY Motif on the Constitutive 
Activity and Structural Instability of the Histamine H2Receptor', Molecular pharmacology, 57: 
890-98. 
Altenbach, Christian, Ana Karin Kusnetzow, Oliver P Ernst, Klaus Peter Hofmann, and Wayne L Hubbell. 
2008. 'High-resolution distance mapping in rhodopsin reveals the pattern of helix movement 
due to activation', Proceedings of the National Academy of Sciences, 105: 7439-44. 
Baki, Lia, Miguel Fribourg, Jason Younkin, Jose Miguel Eltit, Jose L Moreno, Gyu Park, Zhanna Vysotskaya, 
Adishesh Narahari, Stuart C Sealfon, and Javier Gonzalez-Maeso. 2016. 'Cross-signaling in 
metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells', Pflügers 
Archiv-European Journal of Physiology, 468: 775-93. 
Ballesteros, Juan A, Anne D Jensen, George Liapakis, Søren GF Rasmussen, Lei Shi, Ulrik Gether, and 
Jonathan A Javitch. 2001. 'Activation of the β2-adrenergic receptor involves disruption of an 
ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6', Journal of 
Biological Chemistry, 276: 29171-77. 
Baltoumas, Fotis A, Margarita C Theodoropoulou, and Stavros J Hamodrakas. 2013. 'Interactions of the 
α-subunits of heterotrimeric G-proteins with GPCRs, effectors and RGS proteins: a critical review 
and analysis of interacting surfaces, conformational shifts, structural diversity and electrostatic 
potentials', Journal of structural biology, 182: 209-18. 
Benneyworth, Michael A, Randy L Smith, and Elaine Sanders-Bush. 2008. 'Chronic phenethylamine 
hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor 
agonist', Neuropsychopharmacology, 33: 2206. 
Bullock, W Michael, Karen Cardon, Juan Bustillo, Rosalinda C Roberts, and Nora I Perrone-Bizzozero. 
2008. 'Altered expression of genes involved in GABAergic transmission and neuromodulation of 
granule cell activity in the cerebellum of schizophrenia patients', American Journal of Psychiatry, 
165: 1594-603. 
Burford, NT, JR Traynor, and A Alt. 2015. 'Positive allosteric modulators of the μ‐opioid receptor: a novel 
approach for future pain medications', British Journal of Pharmacology, 172: 277-86. 
Carlton, Susan M, Junhui Du, and Shengtai Zhou. 2009. 'Group II metabotropic glutamate receptor 
activation on peripheral nociceptors modulates TRPV1 function', Brain research, 1248: 86-95. 
Carpenter, Byron, Rony Nehmé, Tony Warne, Andrew GW Leslie, and Christopher G Tate. 2016. 
'Structure of the adenosine A 2A receptor bound to an engineered G protein', Nature, 536: 104. 
Cartmell, Jayne, James A Monn, and Darryle D Schoepp. 1999. 'The metabotropic glutamate 2/3 
receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-
amphetamine motor behaviors in rats', Journal of Pharmacology and Experimental Therapeutics, 
291: 161-70. 
Choe, Hui-Woog, Yong Ju Kim, Jung Hee Park, Takefumi Morizumi, Emil F Pai, Norbert Krauss, Klaus 
Peter Hofmann, Patrick Scheerer, and Oliver P Ernst. 2011. 'Crystal structure of metarhodopsin 
II', Nature, 471: 651. 
Christopoulos, Arthur. 2014. 'Advances in G protein-coupled receptor allostery: from function to 
structure', Molecular pharmacology, 86: 463-78. 
Christopoulos, Arthur, Jean-Pierre Changeux, William A Catterall, Doriano Fabbro, Thomas P Burris, John 
A Cidlowski, Richard W Olsen, John A Peters, Richard R Neubig, and Jean-Philippe Pin. 2014. 
'International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: 
  92 
recommendations for the nomenclature of receptor allosterism and allosteric ligands', 
Pharmacological reviews, 66: 918-47. 
Chung, Ka Young, Søren GF Rasmussen, Tong Liu, Sheng Li, Brian T DeVree, Pil Seok Chae, Diane Calinski, 
Brian K Kobilka, Virgil L Woods Jr, and Roger K Sunahara. 2011. 'Conformational changes in the G 
protein Gs induced by the β 2 adrenergic receptor', Nature, 477: 611. 
Coleman, David E, Albert M Berghuis, Ethan Lee, Maurine E Linder, and Alfred G Gilman. 1994. 
'Structures of active conformations of Gi alpha 1 and the mechanism of GTP hydrolysis', science, 
265: 1405-12. 
Conn, P Jeffrey, Arthur Christopoulos, and Craig W Lindsley. 2009. 'Allosteric modulators of GPCRs: a 
novel approach for the treatment of CNS disorders', Nature reviews Drug discovery, 8: 41. 
Costa, Tommaso, and Albert Herz. 1989. 'Antagonists with negative intrinsic activity at delta opioid 
receptors coupled to GTP-binding proteins', Proceedings of the National Academy of Sciences, 
86: 7321-25. 
De Lean, Andre, JMand Stadel, and RJ Lefkowitz. 1980. 'A ternary complex model explains the agonist-
specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor', Journal 
of Biological Chemistry, 255: 7108-17. 
DeVree, Brian T, Jacob P Mahoney, Gisselle A Vélez-Ruiz, Soren GF Rasmussen, Adam J Kuszak, Elin 
Edwald, Juan-Jose Fung, Aashish Manglik, Matthieu Masureel, and Yang Du. 2016. 'Allosteric 
coupling from G protein to the agonist-binding pocket in GPCRs', Nature, 535: 182. 
Doré, Andrew S, Krzysztof Okrasa, Jayesh C Patel, Maria Serrano-Vega, Kirstie Bennett, Robert M Cooke, 
James C Errey, Ali Jazayeri, Samir Khan, and Ben Tehan. 2014. 'Structure of class C GPCR 
metabotropic glutamate receptor 5 transmembrane domain', Nature, 511: 557. 
Doumazane, Etienne, Pauline Scholler, Jurriaan M Zwier, Eric Trinquet, Philippe Rondard, and Jean-
Philippe Pin. 2011. 'A new approach to analyze cell surface protein complexes reveals specific 
heterodimeric metabotropic glutamate receptors', The FASEB Journal, 25: 66-77. 
Dror, Ron O, Thomas J Mildorf, Daniel Hilger, Aashish Manglik, David W Borhani, Daniel H Arlow, Ansgar 
Philippsen, Nicolas Villanueva, Zhongyu Yang, and Michael T Lerch. 2015. 'Structural basis for 
nucleotide exchange in heterotrimeric G proteins', science, 348: 1361-65. 
El Moustaine, Driss, Sébastien Granier, Etienne Doumazane, Pauline Scholler, Rita Rahmeh, Patrick Bron, 
Bernard Mouillac, Jean-Louis Banères, Philippe Rondard, and Jean-Philippe Pin. 2012. 'Distinct 
roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein 
coupling', Proceedings of the National Academy of Sciences, 109: 16342-47. 
Ellaithy, Amr, Jason Younkin, Javier Gonzalez-Maeso, and Diomedes E Logothetis. 2015. 'Positive 
allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment', 
Trends in neurosciences, 38: 506-16. 
Farrens, David L, Christian Altenbach, Ke Yang, Wayne L Hubbell, and H Gobind Khorana. 1996. 
'Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin', 
science, 274: 768-70. 
Fell, Matthew J, Jeffrey M Witkin, Julie F Falcone, Jason S Katner, Kenneth W Perry, John Hart, Linda 
Rorick-Kehn, Carl D Overshiner, Kurt Rasmussen, and Stephen F Chaney. 2011. 'N-(4-((2-
(trifluoromethyl)-3-hydroxy-4-(isobutyryl) phenoxy) methyl) benzyl)-1-methyl-1H-imidazole-4-
carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential 
anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and 
central nervous system neurochemical changes', Journal of Pharmacology and Experimental 
Therapeutics, 336: 165-77. 
Francesconi, Anna, and Robert M Duvoisin. 1998. 'Role of the second and third intracellular loops of 
metabotropic glutamate receptors in mediating dual signal transduction activation', Journal of 
Biological Chemistry, 273: 5615-24. 
  93 
Fribourg, Miguel, José L Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, 
Scott K Adney, Candice Hatcher, and José M Eltit. 2011. 'Decoding the signaling of a GPCR 
heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs', Cell, 147: 
1011-23. 
Ghanouni, Pejman, Zygmunt Gryczynski, Jacqueline J Steenhuis, Tae Weon Lee, David L Farrens, Joseph R 
Lakowicz, and Brian K Kobilka. 2001. 'Functionally Different Agonists Induce Distinct 
Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor', Journal of 
Biological Chemistry, 276: 24433-36. 
Ghose, Subroto, Jeremy M Crook, Cynthia L Bartus, Thomas G Sherman, Mary M Herman, Thomas M 
Hyde, Joel E Kleinman, and Mayada Akil. 2008. 'Metabotropic glutamate receptor 2 and 3 gene 
expression in the human prefrontal cortex and mesencephalon in schizophrenia', International 
Journal of Neuroscience, 118: 1609-27. 
Ghose, Subroto, Kelly A Gleason, Bryan W Potts, Kelly Lewis-Amezcua, and Carol A Tamminga. 2009. 
'Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a 
mechanism for antipsychotic drug action?', American Journal of Psychiatry, 166: 812-20. 
González-Maeso, Javier, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-
Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, and Graeme Milligan. 2008. 
'Identification of a serotonin/glutamate receptor complex implicated in psychosis', Nature, 452: 
93. 
Griebel, Guy, Philippe Pichat, Denis Boulay, Vanessa Naimoli, Lisa Potestio, Robert Featherstone, 
Sukhveen Sahni, Henry Defex, Christophe Desvignes, and Franck Slowinski. 2016. 'The mGluR2 
positive allosteric modulator, SAR218645, improves memory and attention deficits in 
translational models of cognitive symptoms associated with schizophrenia', Scientific reports, 6: 
35320. 
Gupta, Daya S, Robert E McCullumsmith, Monica Beneyto, Vahram Haroutunian, Kenneth L Davis, and 
James H Meador‐Woodruff. 2005. 'Metabotropic glutamate receptor protein expression in the 
prefrontal cortex and striatum in schizophrenia', Synapse, 57: 123-31. 
Gurevich, Vsevolod V, and Eugenia V Gurevich. 2017. 'Molecular Mechanisms of GPCR Signaling: A 
Structural Perspective', International journal of molecular sciences, 18: 2519. 
Hatcher-Solis, Candice, Miguel Fribourg, Katerina Spyridaki, Jason Younkin, Amr Ellaithy, Guoqing Xiang, 
George Liapakis, Javier Gonzalez-Maeso, Hailin Zhang, and Meng Cui. 2014. 'G protein-coupled 
receptor signaling to Kir channels in Xenopus oocytes', Current pharmaceutical biotechnology, 
15: 987-95. 
Hermans, Emmanuel. 2003. 'Biochemical and pharmacological control of the multiplicity of coupling at 
G-protein-coupled receptors', Pharmacology & Therapeutics, 99: 25-44. 
Hilger, Daniel, Matthieu Masureel, and Brian K Kobilka. 2018. 'Structure and dynamics of GPCR signaling 
complexes', Nature structural & molecular biology, 25: 4. 
Hopkins, Corey R. 2013. "Is there a path forward for mGlu2 positive allosteric modulators for the 
treatment of schizophrenia?" In.: ACS Publications. 
Huang, Jianyun, Yutong Sun, J Jillian Zhang, and Xin-Yun Huang. 2015. 'Pivotal Role of Extended Linker 2 
in the Activation of Gα by G Protein-coupled Receptor', Journal of Biological Chemistry, 290: 
272-83. 
Huang, Weijiao, Aashish Manglik, AJ Venkatakrishnan, Toon Laeremans, Evan N Feinberg, Adrian L 
Sanborn, Hideaki E Kato, Kathryn E Livingston, Thor S Thorsen, and Ralf C Kling. 2015. 'Structural 
insights into µ-opioid receptor activation', Nature, 524: 315. 
Isogai, Shin, Xavier Deupi, Christian Opitz, Franziska M Heydenreich, Ching-Ju Tsai, Florian Brueckner, 
Gebhard FX Schertler, Dmitry B Veprintsev, and Stephan Grzesiek. 2016. 'Backbone NMR reveals 
allosteric signal transduction networks in the β 1-adrenergic receptor', Nature, 530: 237. 
  94 
Jazayeri, Ali, Mathieu Rappas, Alastair JH Brown, James Kean, James C Errey, Nathan J Robertson, Cédric 
Fiez-Vandal, Stephen P Andrews, Miles Congreve, and Andrea Bortolato. 2017. 'Crystal structure 
of the GLP-1 receptor bound to a peptide agonist', Nature, 546: 254. 
Johnson, Kari A, and David M Lovinger. 2015. 'Metabotropic Glutamate Receptor 2 Positive Allosteric 
Modulators: Closing the Gate on Drug Abuse?', Biological psychiatry, 78: 436-38. 
Jones, Carrie K, Elizabeth Lutz Eberle, Stephen C Peters, James A Monn, and Harlan E Shannon. 2005. 
'Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists 
LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated 
dosing', Neuropharmacology, 49: 206-18. 
Kammermeier, Paul J, and June Yun. 2005. 'Activation of metabotropic glutamate receptor 1 dimers 
requires glutamate binding in both subunits', Journal of Pharmacology and Experimental 
Therapeutics, 312: 502-08. 
Kenny, Paul J, Fabrizio Gasparini, and Athina Markou. 2003. 'Group II metabotropic and α-amino-3-
hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the 
deficit in brain reward function associated with nicotine withdrawal in rats', Journal of 
Pharmacology and Experimental Therapeutics, 306: 1068-76. 
Kim, Soong Ho, Paul E Fraser, David Westaway, Peter H St George-Hyslop, Michelle E Ehrlich, and Sam 
Gandy. 2010. 'Group II metabotropic glutamate receptor stimulation triggers production and 
release of Alzheimer's amyloid β42 from isolated intact nerve terminals', Journal of 
Neuroscience, 30: 3870-75. 
Kinon, Bruce J, Brian A Millen, Lu Zhang, and David L McKinzie. 2015. 'Exploratory analysis for a targeted 
patient population responsive to the metabotropic glutamate 2/3 receptor agonist 
pomaglumetad methionil in schizophrenia', Biological psychiatry, 78: 754-62. 
Kinon, Bruce J, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, 
Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova, and HBBI Study Group. 2011. 'A 
multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of 
LY2140023 monohydrate in patients with DSM-IV schizophrenia', Journal of clinical 
psychopharmacology, 31: 349-55. 
Kniazeff, Julie, Anne-Sophie Bessis, Damien Maurel, Hervé Ansanay, Laurent Prézeau, and Jean-Philippe 
Pin. 2004. 'Closed state of both binding domains of homodimeric mGlu receptors is required for 
full activity', Nature Structural and Molecular Biology, 11: 706. 
Kniazeff, Julie, Laurent Prézeau, Philippe Rondard, Jean-Philippe Pin, and Cyril Goudet. 2011. 'Dimers 
and beyond: The functional puzzles of class C GPCRs', Pharmacology & Therapeutics, 130: 9-25. 
Kobilka, Brian K, and Xavier Deupi. 2007. 'Conformational complexity of G-protein-coupled receptors', 
Trends in pharmacological sciences, 28: 397-406. 
Kordi-Tamandani, Dor Mohammad, Nahid Dahmardeh, and Adam Torkamanzehi. 2013. 'Evaluation of 
hypermethylation and expression pattern of GMR2, GMR5, GMR8, and GRIA3 in patients with 
schizophrenia', Gene, 515: 163-66. 
Kruse, Andrew C, Aaron M Ring, Aashish Manglik, Jianxin Hu, Kelly Hu, Katrin Eitel, Harald Hübner, Els 
Pardon, Celine Valant, and Patrick M Sexton. 2013. 'Activation and allosteric modulation of a 
muscarinic acetylcholine receptor', Nature, 504: 101. 
Kunishima, Naoki, Yoshimi Shimada, Yuji Tsuji, Toshihiro Sato, Masaki Yamamoto, Takashi Kumasaka, 
Shigetada Nakanishi, Hisato Jingami, and Kosuke Morikawa. 2000. 'Structural basis of glutamate 
recognition by a dimeric metabotropic glutamate receptor', Nature, 407: 971. 
Kurita, Mitsumasa, Terrell Holloway, Aintzane García-Bea, Alexey Kozlenkov, Allyson K Friedman, José L 
Moreno, Mitra Heshmati, Sam A Golden, Pamela J Kennedy, and Nagahide Takahashi. 2012. 
'HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter 
activity', Nature neuroscience, 15: 1245. 
  95 
Lambright, David G, Joseph P Noel, Heidi E Hamm, and Paul B Sigler. 1994. 'Structural determinants for 
activation of the α-subunit of a heterotrimeric G protein', Nature, 369: 621. 
Lambright, David G, John Sondek, Andrew Bohm, Nikolai P Skiba, Heidi E Hamm, and Paul B Sigler. 1996. 
'The 2.0 Å crystal structure of a heterotrimeric G protein', Nature, 379: 311. 
Latorraca, Naomi R, AJ Venkatakrishnan, and Ron O Dror. 2016. 'GPCR dynamics: structures in motion', 
Chemical reviews, 117: 139-55. 
Lefkowitz, R. J. 2007. 'Seven transmembrane receptors: a brief personal retrospective', Biochim Biophys 
Acta, 1768: 748-55. 
Levitz, Joshua, Chris Habrian, Shashank Bharill, Zhu Fu, Reza Vafabakhsh, and Ehud Y Isacoff. 2016. 
'Mechanism of assembly and cooperativity of homomeric and heteromeric metabotropic 
glutamate receptors', Neuron, 92: 143-59. 
Liang, Yi-Lynn, Maryam Khoshouei, Mazdak Radjainia, Yan Zhang, Alisa Glukhova, Jeffrey Tarrasch, David 
M Thal, Sebastian GB Furness, George Christopoulos, and Thomas Coudrat. 2017. 'Phase-plate 
cryo-EM structure of a class B GPCR–G-protein complex', Nature, 546: 118. 
Litman, Robert E, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, and Stephen R 
Zukin. 2016. 'AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not 
improve symptoms in schizophrenia: A proof of principle study', Schizophrenia research, 172: 
152-57. 
Logothetis, Diomedes E, Shahla Movahedi, Carol Satler, Klaus Lindpaintner, and Bernardo Nadal-Ginard. 
1992. 'Incremental reductions of positive charge within the S4 region of a voltage-gated K+ 
channel result in corresponding decreases in gating charge', Neuron, 8: 531-40. 
Mahajan, Rahul, Junghoon Ha, Miao Zhang, Takeharu Kawano, Tohru Kozasa, and Diomedes E 
Logothetis. 2013. 'A computational model predicts that Gβγ acts at a cleft between channel 
subunits to activate GIRK1 channels', Sci. Signal., 6: ra69-ra69. 
Mahoney, Jacob P, and Roger K Sunahara. 2016. 'Mechanistic insights into GPCR–G protein interactions', 
Current opinion in structural biology, 41: 247-54. 
Manglik, Aashish, Tae Hun Kim, Matthieu Masureel, Christian Altenbach, Zhongyu Yang, Daniel Hilger, 
Michael T Lerch, Tong Sun Kobilka, Foon Sun Thian, and Wayne L Hubbell. 2015. 'Structural 
insights into the dynamic process of β2-adrenergic receptor signaling', Cell, 161: 1101-11. 
Manglik, Aashish, and Andrew C Kruse. 2017. 'Structural basis for G protein-coupled receptor activation', 
Biochemistry, 56: 5628-34. 
Marek, Gerard J. 2010. 'Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition', 
European journal of pharmacology, 639: 81-90. 
Mastroiacovo, Federica, Slavianka Moyanova, Milena Cannella, Anderson Gaglione, Remy Verhaeghe, 
Giovanna Bozza, Michele Madonna, Marta Motolese, Anna Traficante, and Barbara Riozzi. 2017. 
'Genetic deletion of mGlu2 metabotropic glutamate receptors improves the short-term 
outcome of cerebral transient focal ischemia', Molecular brain, 10: 39. 
Matrisciano, F, A Caruso, R Orlando, M Marchiafava, V Bruno, G Battaglia, SHM Gruber, D Melchiorri, R 
Tatarelli, and P Girardi. 2008. 'Defective group-II metaboropic glutamate receptors in the 
hippocampus of spontaneously depressed rats', Neuropharmacology, 55: 525-31. 
Metcalf, Cameron S, Brian D Klein, Misty D Smith, Tim Pruess, Marc Ceusters, Hilde Lavreysen, Stefan 
Pype, Nancy Van Osselaer, Roy Twyman, and H Steve White. 2017. 'Efficacy of mGlu2‐positive 
allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of 
psychomotor seizures', Epilepsia, 58: 484-93. 
Milligan, G., and E. Kostenis. 2006. 'Heterotrimeric G-proteins: a short history', British Journal of 
Pharmacology, 147: S46-S55. 
  96 
Mixon, Mark B, Ethan Lee, David E Coleman, Albert M Berghuis, Alfred G Gilman, and Stephen R Sprang. 
1995. 'Tertiary and quaternary structural changes in Giα1 induced by GTP hydrolysis', science, 
270: 954-60. 
Moghaddam, Bita, and Barbara W Adams. 1998. 'Reversal of phencyclidine effects by a group II 
metabotropic glutamate receptor agonist in rats', science, 281: 1349-52. 
Moreno, José L, Terrell Holloway, Laura Albizu, Stuart C Sealfon, and Javier González-Maeso. 2011. 
'Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral 
effects induced by hallucinogenic 5-HT2A receptor agonists', Neuroscience letters, 493: 76-79. 
Moreno, José L, Terrell Holloway, Vinayak Rayannavar, Stuart C Sealfon, and Javier González-Maeso. 
2013. 'Chronic treatment with LY341495 decreases 5-HT2A receptor binding and hallucinogenic 
effects of LSD in mice', Neuroscience letters, 536: 69-73. 
Moreno, José L, Carolina Muguruza, Adrienne Umali, Steven Mortillo, Terrell Holloway, Fuencisla Pilar-
Cuéllar, Giuseppe Mocci, Jeremy Seto, Luis F Callado, and Rachael L Neve. 2012. 'Identification of 
three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A· mGlu2) 
receptor heteromerization and its psychoactive behavioral function', Journal of Biological 
Chemistry, 287: 44301-19. 
Motolese, Marta, Federica Mastroiacovo, Milena Cannella, Domenico Bucci, Anderson Gaglione, Barbara 
Riozzi, Robert Lütjens, Sonia M Poli, Sylvain Celanire, and Valeria Bruno. 2015. 'Targeting type-2 
metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic 
damage', Molecular brain, 8: 66. 
Muguruza, Carolina, J Javier Meana, and Luis F Callado. 2016. 'Group II metabotropic glutamate 
receptors as targets for novel antipsychotic drugs', Frontiers in pharmacology, 7: 130. 
Nakanishi, Shigetada. 1992. 'Molecular diversity of glutamate receptors and implications for brain 
function', science, 258: 597-603. 
Noel, Joseph P, Heidi E Hamm, and Paul B Sigler. 1993. 'The 2.2 Å crystal structure of transducin-α 
complexed with GTPγS', Nature, 366: 654. 
Nygaard, Rie, Yaozhong Zou, Ron O Dror, Thomas J Mildorf, Daniel H Arlow, Aashish Manglik, Albert C 
Pan, Corey W Liu, Juan José Fung, and Michael P Bokoch. 2013. 'The dynamic process of β2-
adrenergic receptor activation', Cell, 152: 532-42. 
Oldham, William M, and Heidi E Hamm. 2008. 'Heterotrimeric G protein activation by G-protein-coupled 
receptors', Nature reviews Molecular cell biology, 9: 60. 
Palczewski, Krzysztof, Takashi Kumasaka, Tetsuya Hori, Craig A Behnke, Hiroyuki Motoshima, Brian A 
Fox, Isolde Le Trong, David C Teller, Tetsuji Okada, and Ronald E Stenkamp. 2000. 'Crystal 
structure of rhodopsin: AG protein-coupled receptor', science, 289: 739-45. 
Patil, Sandeep T, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla 
S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, and Margarita A Morozova. 2007. 
'Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 
2 clinical trial', Nature medicine, 13: 1102. 
Rasmussen, S. G., H. J. Choi, D. M. Rosenbaum, T. S. Kobilka, F. S. Thian, P. C. Edwards, M. Burghammer, 
V. R. Ratnala, R. Sanishvili, R. F. Fischetti, G. F. Schertler, W. I. Weis, and B. K. Kobilka. 2007. 
'Crystal structure of the human beta2 adrenergic G-protein-coupled receptor', Nature, 450: 383-
7. 
Rasmussen, Søren GF, Hee-Jung Choi, Juan Jose Fung, Els Pardon, Paola Casarosa, Pil Seok Chae, Brian T 
DeVree, Daniel M Rosenbaum, Foon Sun Thian, and Tong Sun Kobilka. 2011. 'Structure of a 
nanobody-stabilized active state of the β 2 adrenoceptor', Nature, 469: 175. 
Rasmussen, Søren GF, Brian T DeVree, Yaozhong Zou, Andrew C Kruse, Ka Young Chung, Tong Sun 
Kobilka, Foon Sun Thian, Pil Seok Chae, Els Pardon, and Diane Calinski. 2011. 'Crystal structure of 
the β 2 adrenergic receptor–Gs protein complex', Nature, 477: 549. 
  97 
Rasmussen, Søren GF, Anne D Jensen, George Liapakis, Pejman Ghanouni, Jonathan A Javitch, and Ulrik 
Gether. 1999. 'Mutation of a highly conserved aspartic acid in the β2 adrenergic receptor: 
constitutive activation, structural instability, and conformational rearrangement of 
transmembrane segment 6', Molecular pharmacology, 56: 175-84. 
Ray, Kausik, and Benjamin C Hauschild. 2000. 'Cys-140 is critical for metabotropic glutamate receptor-1 
dimerization', Journal of Biological Chemistry, 275: 34245-51. 
Reiner, Andreas, Joshua Levitz, and Ehud Y Isacoff. 2015. 'Controlling ionotropic and metabotropic 
glutamate receptors with light: principles and potential', Current opinion in pharmacology, 20: 
135-43. 
Richards, Grayson, Jürg Messer, Richard LM Faull, Heinz Stadler, Jürgen Wichmann, Philipp Huguenin, 
Bernd Bohrmann, and Vincent Mutel. 2010. 'Altered distribution of mGlu2 receptors in β-
amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice', Brain research, 1363: 
180-90. 
Romano, Carmelo, Wan-Lin Yang, and Karen L O'Malley. 1996. 'Metabotropic glutamate receptor 5 is a 
disulfide-linked dimer', Journal of Biological Chemistry, 271: 28612-16. 
Rondard, Philippe, and Jean-Philippe Pin. 2015. 'Dynamics and modulation of metabotropic glutamate 
receptors', Current opinion in pharmacology, 20: 95-101. 
Rusinova, Radda, Tooraj Mirshahi, and Diomedes E Logothetis. 2007. 'Specificity of Gβγ signaling to Kir3 
channels depends on the helical domain of pertussis toxin-sensitive Gα subunits', Journal of 
Biological Chemistry, 282: 34019-30. 
Samama, Pa, S Cotecchia, T Costa, and RJ Lefkowitz. 1993. 'A mutation-induced activated state of the 
beta 2-adrenergic receptor. Extending the ternary complex model', Journal of Biological 
Chemistry, 268: 4625-36. 
Sanacora, Gerard, Carlos A Zarate, John H Krystal, and Husseini K Manji. 2008. 'Targeting the 
glutamatergic system to develop novel, improved therapeutics for mood disorders', Nature 
reviews Drug discovery, 7: 426. 
Scheer, A, F Fanelli, T Costa, PG De Benedetti, and S Cotecchia. 1996. 'Constitutively active mutants of 
the alpha 1B‐adrenergic receptor: role of highly conserved polar amino acids in receptor 
activation', The EMBO Journal, 15: 3566-78. 
Scheer, Alexander, Francesca Fanelli, Tommaso Costa, Pier G De Benedetti, and Susanna Cotecchia. 
1997. 'The activation process of the α1B-adrenergic receptor: potential role of protonation and 
hydrophobicity of a highly conserved aspartate', Proceedings of the National Academy of 
Sciences, 94: 808-13. 
Scheerer, Patrick, Jung Hee Park, Peter W Hildebrand, Yong Ju Kim, Norbert Krauß, Hui-Woog Choe, 
Klaus Peter Hofmann, and Oliver P Ernst. 2008. 'Crystal structure of opsin in its G-protein-
interacting conformation', Nature, 455: 497. 
Schoepp, Darryle D. 2001. 'Unveiling the functions of presynaptic metabotropic glutamate receptors in 
the central nervous system', Journal of Pharmacology and Experimental Therapeutics, 299: 12-
20. 
Schwartz, Thomas L, Shilpa Sachdeva, and Stephen M Stahl. 2012. 'Glutamate neurocircuitry: theoretical 
underpinnings in schizophrenia', Frontiers in pharmacology, 3: 195. 
Seifert, Roland, and Katharina Wenzel-Seifert. 2002. 'Constitutive activity of G-protein-coupled 
receptors: cause of disease and common property of wild-type receptors', Naunyn-
Schmiedeberg's archives of pharmacology, 366: 381-416. 
Shapiro, David A, Kurt Kristiansen, David M Weiner, Wesley K Kroeze, and Bryan L Roth. 2002. 'Evidence 
for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that 
involves the disruption of a strong ionic interaction between helices 3 and 6', Journal of 
Biological Chemistry, 277: 11441-49. 
  98 
Sondek, John, David G Lambright, Joseph P Noel, Heidi E Hamm, and Paul B Sigler. 1994. 'GTPase 
mechanism of Gproteins from the 1.7-Å crystal structure of transducin α-GDP AIF− 4', Nature, 
372: 276. 
Sounier, Rémy, Camille Mas, Jan Steyaert, Toon Laeremans, Aashish Manglik, Weijiao Huang, Brian K 
Kobilka, Héléne Déméné, and Sébastien Granier. 2015. 'Propagation of conformational changes 
during μ-opioid receptor activation', Nature, 524: 375. 
Sprang, Stephen R. 2016. 'Invited review: Activation of G proteins by GTP and the mechanism of Gα‐
catalyzed GTP hydrolysis', Biopolymers, 105: 449-62. 
Standfuss, Jörg, Patricia C Edwards, Aaron D’Antona, Maikel Fransen, Guifu Xie, Daniel D Oprian, and 
Gebhard FX Schertler. 2011. 'The structural basis of agonist-induced activation in constitutively 
active rhodopsin', Nature, 471: 656. 
Stewart, Gregory, Julie Kniazeff, Laurent Prézeau, Philippe Rondard, Jean-Philippe Pin, and Cyril Goudet. 
2012. 'Metabotropic Receptors for Glutamate and GABA.' in, Pharmacology (InTech). 
Strader, Catherine D, Irving S Sigal, and RA Dixon. 1989. 'Structural basis of beta-adrenergic receptor 
function', The FASEB Journal, 3: 1825-32. 
Sunahara, Roger K, John JG Tesmer, Alfred G Gilman, and Stephen R Sprang. 1997. 'Crystal structure of 
the adenylyl cyclase activator Gsα', science, 278: 1943-47. 
Thaker, Tarjani M, Maruf Sarwar, Anita M Preininger, Heidi E Hamm, and TM Iverson. 2014. 'A transient 
interaction between the phosphate binding loop and switch I contributes to the allosteric 
network between receptor and nucleotide in Gαi1', Journal of Biological Chemistry, 289: 11331-
41. 
Therapeutics, Addex. 2012. "Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with 
ADX71149 in Schizophrenia Patients." In.: Addex Therapeutics Press Release. 
Tizzano, Joseph P, Kelly I Griffey, and Darryle D Schoepp. 2002. 'The anxiolytic action of mGlu2/3 
receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically 
distinct from diazepam', Pharmacology Biochemistry and Behavior, 73: 367-74. 
Ulloa-Aguirre, Alfredo, Aída Uribe, Teresa Zariñán, Ismael Bustos-Jaimes, Marco A Pérez-Solis, and James 
A Dias. 2007. 'Role of the intracellular domains of the human FSH receptor in Gαs protein 
coupling and receptor expression', Molecular and cellular endocrinology, 260: 153-62. 
Urban, Jonathan D, William P Clarke, Mark Von Zastrow, David E Nichols, Brian Kobilka, Harel Weinstein, 
Jonathan A Javitch, Bryan L Roth, Arthur Christopoulos, and Patrick M Sexton. 2007. 'Functional 
selectivity and classical concepts of quantitative pharmacology', Journal of Pharmacology and 
Experimental Therapeutics, 320: 1-13. 
Vauquelin, Georges, and Bengt Von Mentzer. 2008. G protein-coupled receptors: Molecular 
pharmacology (John Wiley & Sons). 
Vogel, Reiner, Mohana Mahalingam, Steffen Lüdeke, Thomas Huber, Friedrich Siebert, and Thomas P 
Sakmar. 2008. 'Functional role of the “ionic lock”—an interhelical hydrogen-bond network in 
family A heptahelical receptors', Journal of molecular biology, 380: 648-55. 
Wacker, D., R. C. Stevens, and B. L. Roth. 2017. 'How Ligands Illuminate GPCR Molecular Pharmacology', 
Cell, 170: 414-27. 
Wang, Sheng, Tao Che, Anat Levit, Brian K Shoichet, Daniel Wacker, and Bryan L Roth. 2018. 'Structure of 
the D 2 dopamine receptor bound to the atypical antipsychotic drug risperidone', Nature. 
Witkin, JM, JA Monn, DD Schoepp, X Li, C Overshiner, SN Mitchell, G Carter, B Johnson, K Rasmussen, 
and LM Rorick-Kehn. 2016. 'The rapidly acting antidepressant ketamine and the mGlu2/3 
receptor antagonist LY341495 rapidly engage dopaminergic mood circuits', Journal of 
Pharmacology and Experimental Therapeutics, 358: 71-82. 
  99 
Wu, Huixian, Chong Wang, Karen J Gregory, Gye Won Han, Hyekyung P Cho, Yan Xia, Colleen M 
Niswender, Vsevolod Katritch, Jens Meiler, and Vadim Cherezov. 2014. 'Structure of a class C 
GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator', science, 344: 58-64. 
Yang, Hong-Ju, Hai-Ying Zhang, Guo-Hua Bi, Yi He, Jun-Tao Gao, and Zheng-Xiong Xi. 2017. 'Deletion of 
Type 2 Metabotropic Glutamate Receptor Decreases Sensitivity to Cocaine Reward in Rats', Cell 
reports, 20: 319-32. 
Yao, Xiao Jie, Gisselle Vélez Ruiz, Matthew R Whorton, Søren GF Rasmussen, Brian T DeVree, Xavier 
Deupi, Roger K Sunahara, and Brian Kobilka. 2009. 'The effect of ligand efficacy on the formation 
and stability of a GPCR-G protein complex', Proceedings of the National Academy of Sciences, 
106: 9501-06. 
Zhang, Yan, Bingfa Sun, Dan Feng, Hongli Hu, Matthew Chu, Qianhui Qu, Jeffrey T Tarrasch, Shane Li, 
Tong Sun Kobilka, and Brian K Kobilka. 2017. 'Cryo-EM structure of the activated GLP-1 receptor 
in complex with a G protein', Nature, 546: 248. 
 
  
  100 
Vita 
Birthdate: July 1, 1989  
Birthplace: Dakahliya, Egypt  
Citizenship: Egypt 
 
Education 
 
Awards and Honors 
May 2016 Robert W. Ramsey Award, VCU 
Phi Kappa Phi honor society award 
Charles C. Clayton award  
May 2014 VCU Global Education Office Travel Award to participate in the Erice course on 
Biophysics of channels and transporters. International School of Biophysics, Erice, 
Sicily, Italy.  
June 2012 Mansoura University Travel Grant to present a poster at the 19th International 
Student Congress of Medical Sciences (ISCOMS). University Medical Center 
Groningen (UMCG), Groningen, Netherlands. 
Best poster presentation in Neurology, 19th ISCOMS 
ISCOMS Research Fellowship 
May 2012  World Hellenic Biomedical Association (WHBA) Scholarship  
2007-2012 Mansoura University Dean’s list  
 
Publications 
1. Younkin J*, Gaitonde SA*, Ellaithy A*, Vekariya R, Baki L, Moreno JL, Shah S, 
Hideshima KS, Eltit JM, González-Maeso, J Logothetis DE, Dukat M, Glennon RA. 
Reformulating a Pharmacophore for 5-HT2A Serotonin Receptor Antagonists. ACS Chem 
Neurosci. 2016;7(9):1292-9. 
2018 Ph.D. Neuroscience, Virginia Commonwealth University School of Medicine, 
Richmond, VA 
2013 MB BCh Mansoura Manchester Programme for Medical Education, Mansoura 
University, Egypt 
  101 
* Co-First/Equal authorship 
2. Ellaithy A, Younkin J, Gonzalez-Maeso J, Logothetis DE. Positive allosteric modulators of 
metabotropic glutamate 2 receptors in schizophrenia treatment. Trends Neurosci. 2015; 
38:506-16. 
3. Hatcher-Solis C, Fribourg M, Spyridaki K, Younkin J, Ellaithy A, Xiang G, Liapakis G, 
Gonzalez-Maeso J, Zhang H, Cui M, Logothetis DE. G protein-coupled receptor signaling 
to kir channels in Xenopus oocytes.    Curr Pharm Biotechnol. 2014;15:987-95. 
4. Salama M, Helmy B, El-Gamal M, Reda A, Ellaithy A, Tantawy D, Mohamed M, El-
Gamal A, Sheashaa H, Sobh M. Role of L-thyroxine in counteracting rotenone induced 
neurotoxicity in rats. Environ Toxicol Pharmacol. 2013;35:270-7. 
5. Salama M, Ellaithy A, Helmy B, El-Gamal M, Tantawy D, Mohamed M, Sheashaa H, Sobh 
M, Arias-Carrión O. Colchicine Protects Dopaminergic Neurons in a Rat Model of 
Parkinson's Disease. CNS Neurol Disord Drug Targets. 2012;11:836-43.  
 
Abstracts 
1. Ellaithy A, Xu Y, Kawano T, Gonzalez-Maeso J, Logothetis D. Ionic Lock: Functional Role in 
Activation of Metabotropic Glutamate Receptor 2. Poster presentation at Chemistry and 
Pharmacology of Drug Abuse (CPDA) conference, Boston, MA, August 2017.  
2. Xu Y, Ellaithy A, Kawano T, Gonzalez-Maeso J, Logothetis D. Ionic Lock: Functional Role in 
Activation of Metabotropic Glutamate Receptor 2. Biophysical Journal. 2017;112(3):530a. Poster 
presentation at Biophysical Society meeting, New Orleans, LA, February 2017.  
3. Ellaithy A, Younkin J, Baki L, Logothetis DE. A positive allosteric modulator of metabotropic 
glutamate 2 receptor alters 5-HT2A receptor signaling in a heteromeric complex. Poster presentation 
at Biophysical Society meeting, Baltimore, MD, February 2015.  
4. Ellaithy A, Helmy B, Salama M. Does Colchicine possess a neuroprotective effect in Parkinson's 
disease?  Poster presentation at University Medical Center Groningen ISCOMS, June 2012, 
Netherlands.  
 
 
 
 
